<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Cancers (Basel)</journal-id>
<journal-id journal-id-type="iso-abbrev">Cancers (Basel)</journal-id>
<journal-id journal-id-type="publisher-id">cancers</journal-id>
<journal-title-group>
<journal-title>Cancers</journal-title>
</journal-title-group>
<issn pub-type="epub">2072-6694</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31216739</article-id>
<article-id pub-id-type="pmc">6627214</article-id>
<article-id pub-id-type="doi">10.3390/cancers11060844</article-id>
<article-id pub-id-type="publisher-id">cancers-11-00844</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>PTEN</italic> Hamartoma Tumor Syndrome: A Clinical Overview</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7894-1482</contrib-id>
<name>
<surname>Pilarski</surname>
<given-names>Robert</given-names>
</name>
</contrib>
</contrib-group>
<aff id="af1-cancers-11-00844">Division of Human Genetics, Department of Internal Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43221, USA; <email>Robert.pilarski@osumc.edu</email>; Tel.: +1-614-293-7774; Fax: +1-614-293-2314</aff>
<pub-date pub-type="epub">
<day>18</day>
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>6</month>
<year>2019</year>
</pub-date>
<volume>11</volume>
<issue>6</issue>
<elocation-id>844</elocation-id>
<history>
<date date-type="received">
<day>09</day>
<month>5</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>6</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 by the author.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>The phosphatase and tensin homolog (<italic>PTEN)</italic> hamartoma tumor syndrome (PHTS) is a grouping of related genetic disorders that has been linked to germline mutations in the <italic>PTEN</italic> gene. These disorders include Cowden syndrome (CS), Bannayan–Riley–Ruvalcaba syndrome, adult Lhermitte–Duclos disease, and autism spectrum disorders associated with macrocephaly. The majority of the clinical information available on PHTS, however, is related to individuals diagnosed with CS. There is still much to be learned about this disorder, since diagnostic criteria for CS were only established in 1996, before the identification of the <italic>PTEN</italic> gene, and were based primarily on features seen in cases reported in the existing literature. More recently, however, data from several large series of patients have shown that a number of the clinical features associated with <italic>PTEN</italic> mutations are either more or less common than previously reported. In addition, we now know that only about 30–35% of patients meeting clinical diagnostic criteria for Cowden syndrome actually have a detectable <italic>PTEN</italic> mutation. Thus, our understanding of <italic>PTEN</italic>-related diseases and their management has evolved significantly over time. The United States National Comprehensive Cancer Network (NCCN) has produced and regularly updates practice guidelines which include clinical diagnostic criteria as well as guidelines for <italic>PTEN</italic> testing and management of patients with mutations. This review will summarize the overall literature on PHTS as well as recent findings which are broadening our understanding of this set of disorders.</p>
</abstract>
<kwd-group>
<kwd>PTEN</kwd>
<kwd>PHTS</kwd>
<kwd><italic>PTEN</italic> harmartoma tumor syndrome</kwd>
<kwd>cowden syndrome</kwd>
<kwd>Bannayan-Ruvalcaba-Riley syndrome</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-cancers-11-00844" sec-type="intro">
<title>1. Introduction</title>
<p><italic>PTEN</italic> hamartoma tumor syndrome (PHTS) refers to a spectrum of disorders that have been linked to germline mutations in the <italic>PTEN</italic> gene. These include Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, adult Lhermitte–Duclos disease, and autism spectrum disorders associated with macrocephaly. The majority of the published data, however, address patients with Cowden syndrome, and risks must be extrapolated to the other conditions. To date there is insufficient evidence of a correlation between specific <italic>PTEN</italic> mutations and clinical presentations.</p>
<p>Cowden syndrome (CS) is a rare, multi-system disease that was first described in one family in 1963 [<xref ref-type="bibr" rid="B1-cancers-11-00844">1</xref>]. It entails increased risks for malignancies of a number of organs (particularly breast, thyroid and endometrium) and benign overgrowth of a number of tissues (skin, colon, thyroid, etc.). Germline <italic>PTEN</italic> mutations were first reported in individuals with CS in 1997 [<xref ref-type="bibr" rid="B2-cancers-11-00844">2</xref>,<xref ref-type="bibr" rid="B3-cancers-11-00844">3</xref>].</p>
<p>Bannayan-Riley-Ruvalcaba syndrome (BRRS) is a rare pediatric disorder that was initially felt to be distinct from CS. The most common clinical features include macrocephaly, hamartomatous intestinal polyps, lipomas, and pigmented macules on the penis. Other reported features include developmental delay, vascular anomalies, large birth weight, and joint hyperextensibility [<xref ref-type="bibr" rid="B4-cancers-11-00844">4</xref>]. BRRS has been shown to be allelic to CS, with approximately 60% of patients having <italic>PTEN</italic> mutations [<xref ref-type="bibr" rid="B5-cancers-11-00844">5</xref>,<xref ref-type="bibr" rid="B6-cancers-11-00844">6</xref>]. No other genes are known to cause BRRS. However, there are relatively few data on the clinical features of BRRS patients with documented <italic>PTEN</italic> mutations [<xref ref-type="bibr" rid="B7-cancers-11-00844">7</xref>].</p>
<p>There is broad variability in the clinical presentation of patients with <italic>PTEN</italic> mutations, even between patients with the same mutation and patients in the same family. Indeed, families have been reported in which one or more individuals met CS diagnostic criteria while others met BRRS criteria [<xref ref-type="bibr" rid="B5-cancers-11-00844">5</xref>,<xref ref-type="bibr" rid="B8-cancers-11-00844">8</xref>,<xref ref-type="bibr" rid="B9-cancers-11-00844">9</xref>,<xref ref-type="bibr" rid="B10-cancers-11-00844">10</xref>]. While a clear genotype/phenotype correlation has not been shown with <italic>PTEN</italic>, there is some evidence that mutations leading to stable but inactive proteins produce a more severe phenotype than mutations leading to proteins with partially retained function [<xref ref-type="bibr" rid="B11-cancers-11-00844">11</xref>]. Spinelli et al. reported that all seven autism-associated mutations that they studied led to proteins that retained the ability to suppress AKT signaling [<xref ref-type="bibr" rid="B12-cancers-11-00844">12</xref>]. Studies in mice suggest that tumor presentation is dependent on the genetic background of the animal, but the implications for humans with <italic>PTEN</italic> mutations are unclear [<xref ref-type="bibr" rid="B13-cancers-11-00844">13</xref>].</p>
<p>Consensus diagnostic criteria for CS were initially established in 1996 by an international research consortium. This was prior to identification of the CS gene and the criteria were based upon early clinical experience and compilations of cases published in the literature, with their inherent ascertainment biases [<xref ref-type="bibr" rid="B14-cancers-11-00844">14</xref>]. The single largest patient series in any of these reports comprised 21 patients [<xref ref-type="bibr" rid="B15-cancers-11-00844">15</xref>]. It was not until 2013 that an evidence-based review led to a significant revision of the diagnostic criteria (summarized in <xref ref-type="table" rid="cancers-11-00844-t001">Table 1</xref>), which were then adopted by the U.S. National Comprehensive Cancer Network [<xref ref-type="bibr" rid="B16-cancers-11-00844">16</xref>,<xref ref-type="bibr" rid="B17-cancers-11-00844">17</xref>].</p>
<p>It was initially reported, based on small series, that <italic>PTEN</italic> mutations were found in 80% of patients with CS [<xref ref-type="bibr" rid="B3-cancers-11-00844">3</xref>,<xref ref-type="bibr" rid="B18-cancers-11-00844">18</xref>]. More recently, in much larger cohorts, <italic>PTEN</italic> mutations have been found in only 30–35% of patients meeting consortium diagnostic criteria and in 23/42 (55%) patients with a clinical diagnosis of BRRS [<xref ref-type="bibr" rid="B6-cancers-11-00844">6</xref>,<xref ref-type="bibr" rid="B19-cancers-11-00844">19</xref>]. Importantly, 63/172 (37%) patients with mutations in one of these studies did not meet diagnostic criteria for either CS or BRRS [<xref ref-type="bibr" rid="B6-cancers-11-00844">6</xref>]. It is estimated that at least 11%, and perhaps as many as 48%, of patients have de novo mutations [<xref ref-type="bibr" rid="B20-cancers-11-00844">20</xref>].</p>
<p>The National Comprehensive Cancer Network (NCCN) has established criteria for when <italic>PTEN</italic> testing is indicated based on the clinical features present in a patient, as well as management and screening recommendations for individuals who are found to have a <italic>PTEN</italic> mutation [<xref ref-type="bibr" rid="B16-cancers-11-00844">16</xref>]. As noted above, they have also adopted revised clinical diagnostic criteria since patient management is sometimes based on a clinical diagnosis alone if either testing is not possible or it is done but no mutation is found.</p>
<p>This paper reviews the current understanding of the clinical features that are most clearly associated with <italic>PTEN</italic> mutations.</p>
</sec>
<sec id="sec2-cancers-11-00844">
<title>2. Cancer/Tumor Risks</title>
<p>The risks for breast, uterine, thyroid, and colon cancer and Lhermitte-Duclos disease are clearly increased in individuals with <italic>PTEN</italic> mutations. The magnitude of these risks, however, is less certain. The association of <italic>PTEN</italic> mutations with other tumor types is less clear. Each of these is discussed further below.</p>
<sec id="sec2dot1-cancers-11-00844">
<title>2.1. Brain Tumors</title>
<p>Lhermitte-Duclos disease (LDD, dysplastic gangliocytoma of the cerebellum) is a rare, slow growing hamartoma which is usually diagnosed when patients are in their twenties or thirties. While it appears to be clearly associated with <italic>PTEN</italic> mutations, the incidence of LDD in patients with CS is unknown [<xref ref-type="bibr" rid="B21-cancers-11-00844">21</xref>]. A prevalence of 1.8% (3/172) was found in patients undergoing clinical <italic>PTEN</italic> testing [<xref ref-type="bibr" rid="B6-cancers-11-00844">6</xref>], of 6% (18/290) in patients in a research cohort [<xref ref-type="bibr" rid="B19-cancers-11-00844">19</xref>], and of 15% in cases reported in the literature. [<xref ref-type="bibr" rid="B22-cancers-11-00844">22</xref>] Wei et al. found that five of seven adults with LDD had features of PHTS, although <italic>PTEN</italic> testing was not done [<xref ref-type="bibr" rid="B23-cancers-11-00844">23</xref>]. Based on a small study of unselected LDD tumors from 15 adults and three children, it appears that adult-onset LDD is more strongly associated with <italic>PTEN</italic> mutations than childhood-onset LDD [<xref ref-type="bibr" rid="B24-cancers-11-00844">24</xref>]. In another review of 14 children with LDD, three had clinical diagnoses of CS, eight had no signs of the disease, and three had insufficient information to determine a diagnosis [<xref ref-type="bibr" rid="B25-cancers-11-00844">25</xref>].</p>
<p>While various case reports have suggested that a variety of other brain tumors are linked to <italic>PTEN</italic> mutations, the true spectrum and frequency of brain lesions is unknown since brain imaging is rarely done on asymptomatic individuals. Only one report of brain magnetic resonance imaging (MRI) in asymptomatic CS patients has been published [<xref ref-type="bibr" rid="B26-cancers-11-00844">26</xref>]. In this study, seven of 20 patients (mean age 42 years) had brain abnormalities (including three patients with LDD): six had venous and cavernous angiomas, and one had a meningioma. Although multiple cases of meningioma have now been reported in CS (reviewed in Lok et al. [<xref ref-type="bibr" rid="B26-cancers-11-00844">26</xref>] and Yabubov et al. [<xref ref-type="bibr" rid="B27-cancers-11-00844">27</xref>]), no systematic study has been done and their prevalence in PHTS is unknown. Lok et al. found hamartomatous vascular malformations in almost a third of their patients [<xref ref-type="bibr" rid="B26-cancers-11-00844">26</xref>].</p>
</sec>
<sec id="sec2dot2-cancers-11-00844">
<title>2.2. Breast Cancer</title>
<p>Although initially not regarded as being part of the syndrome, breast cancer has long been recognized as the most common CS malignancy. The age of onset appears to be young (average age 38–50 years), and the lifetime risk is typically quoted to be 25–50% [<xref ref-type="bibr" rid="B6-cancers-11-00844">6</xref>,<xref ref-type="bibr" rid="B15-cancers-11-00844">15</xref>,<xref ref-type="bibr" rid="B19-cancers-11-00844">19</xref>,<xref ref-type="bibr" rid="B28-cancers-11-00844">28</xref>,<xref ref-type="bibr" rid="B29-cancers-11-00844">29</xref>]. Several more recent reports have projected the lifetime risk of breast cancer to be 77–85% in several cohorts [<xref ref-type="bibr" rid="B22-cancers-11-00844">22</xref>,<xref ref-type="bibr" rid="B30-cancers-11-00844">30</xref>,<xref ref-type="bibr" rid="B31-cancers-11-00844">31</xref>]. Selection bias was a significant issue in each of these studies, however, as lifetime risks were projected based on the prevalence of breast cancer in the patients who presented for testing (which typically includes those most likely to have cancer). Thus, while breast cancer risk is clearly increased in individuals with <italic>PTEN</italic> mutations, there remains debate as to the degree of that risk. Three males with <italic>PTEN</italic> mutations and breast cancer have been reported [<xref ref-type="bibr" rid="B18-cancers-11-00844">18</xref>,<xref ref-type="bibr" rid="B32-cancers-11-00844">32</xref>,<xref ref-type="bibr" rid="B33-cancers-11-00844">33</xref>], but male breast cancer was not seen in the two largest cohorts reported to date, and a possible association with male breast cancer remains unproven [<xref ref-type="bibr" rid="B6-cancers-11-00844">6</xref>,<xref ref-type="bibr" rid="B19-cancers-11-00844">19</xref>].</p>
</sec>
<sec id="sec2dot3-cancers-11-00844">
<title>2.3. Gastrointestinal Cancer</title>
<p>Although it was originally felt that <italic>PTEN</italic> mutations did not increase the risk for colon cancer [<xref ref-type="bibr" rid="B34-cancers-11-00844">34</xref>], more recent data has shown otherwise. Several studies have shown the prevalence of colon cancer (often early-onset) in several <italic>PTEN</italic> mutation-carrier cohorts to be 9–13% [<xref ref-type="bibr" rid="B35-cancers-11-00844">35</xref>,<xref ref-type="bibr" rid="B36-cancers-11-00844">36</xref>]. Two later publications predicted lifetime colon cancer risks of 9% (Confidence Interval (CI) 3.8–14.1%) and 16% (CI 8–24%), although both were limited by ascertainment biases common in PHTS studies [<xref ref-type="bibr" rid="B22-cancers-11-00844">22</xref>,<xref ref-type="bibr" rid="B31-cancers-11-00844">31</xref>]. A small study from the Mayo Clinic found colon cancer in two of 13 CS patients [<xref ref-type="bibr" rid="B37-cancers-11-00844">37</xref>].</p>
<p>There are at least four reports of gastric cancer in CS patients, but at this point it is not considered part of the PHTS spectrum [<xref ref-type="bibr" rid="B34-cancers-11-00844">34</xref>,<xref ref-type="bibr" rid="B38-cancers-11-00844">38</xref>,<xref ref-type="bibr" rid="B39-cancers-11-00844">39</xref>,<xref ref-type="bibr" rid="B40-cancers-11-00844">40</xref>].</p>
</sec>
<sec id="sec2dot4-cancers-11-00844">
<title>2.4. Endometrial Cancer</title>
<p>Endometrial cancer was found in 14.1% and 7.6% of female <italic>PTEN</italic> mutation carriers in two large research series [<xref ref-type="bibr" rid="B6-cancers-11-00844">6</xref>,<xref ref-type="bibr" rid="B19-cancers-11-00844">19</xref>], and in 17% of clinically tested adult females in another cohort, with the greatest increase in women under age 50 [<xref ref-type="bibr" rid="B6-cancers-11-00844">6</xref>]. As noted above with breast cancer, three studies on cancer risks in <italic>PTEN</italic> mutation carriers have projected an increased lifetime risk of endometrial cancer ranging from 19 to 28% at age 70, but each suffers from ascertainment bias [<xref ref-type="bibr" rid="B22-cancers-11-00844">22</xref>,<xref ref-type="bibr" rid="B30-cancers-11-00844">30</xref>,<xref ref-type="bibr" rid="B31-cancers-11-00844">31</xref>]. Among 54 families in another study with uterine and breast cancers and at least one other <italic>PTEN</italic>-related cancer, no <italic>PTEN</italic> mutations were identified [<xref ref-type="bibr" rid="B41-cancers-11-00844">41</xref>]. In contrast, 7% of a cohort of endometrial cancer patients with features of Cowden syndrome had <italic>PTEN</italic> mutations in another report, although it is not possible to tell from the data how many of these met CS/PHTS diagnostic criteria [<xref ref-type="bibr" rid="B42-cancers-11-00844">42</xref>]. Among 381 endometrial cancer patients who underwent screening for Lynch syndrome, one had a <italic>PTEN</italic> mutation [<xref ref-type="bibr" rid="B43-cancers-11-00844">43</xref>]. Among unselected case of endometrial cancer inherited <italic>PTEN</italic> mutations are quite rare [<xref ref-type="bibr" rid="B44-cancers-11-00844">44</xref>].</p>
</sec>
<sec id="sec2dot5-cancers-11-00844">
<title>2.5. Melanoma</title>
<p>Various case reports have suggested that melanoma risk may be increased in individuals with <italic>PTEN</italic> mutations [<xref ref-type="bibr" rid="B45-cancers-11-00844">45</xref>,<xref ref-type="bibr" rid="B46-cancers-11-00844">46</xref>,<xref ref-type="bibr" rid="B47-cancers-11-00844">47</xref>,<xref ref-type="bibr" rid="B48-cancers-11-00844">48</xref>]. However it was found in only about 1% (2/172) of patients with mutations in one recent cohort, although the mean age of the cohort was only 30 years [<xref ref-type="bibr" rid="B6-cancers-11-00844">6</xref>]. More recently, one group projected a 6% lifetime risk for melanoma (based on nine cases of melanoma reported among 368 patients with mutations) while a second projected standardized incidence ratios (SIRs) of 28.3 in women and 39.4 in men, (based on nine cases among 154 mutation-positive patients) [<xref ref-type="bibr" rid="B30-cancers-11-00844">30</xref>,<xref ref-type="bibr" rid="B31-cancers-11-00844">31</xref>]. The lifetime risk of developing melanoma in the United States is almost 2.8% [<xref ref-type="bibr" rid="B49-cancers-11-00844">49</xref>]. Given this limited evidence, melanoma is not included as a diagnostic criterion for PHTS and more data are needed regarding its association with <italic>PTEN</italic>.</p>
</sec>
<sec id="sec2dot6-cancers-11-00844">
<title>2.6. Thyroid Cancer</title>
<p>Historically, the lifetime risk of thyroid cancer in <italic>PTEN</italic> mutation carriers was estimated to be 3–10% [<xref ref-type="bibr" rid="B50-cancers-11-00844">50</xref>]. However, recent analyses of two cohorts of <italic>PTEN</italic> mutation carriers (with the same ascertainment biases noted above for other cancers) have projected lifetime risks of 35–38% [<xref ref-type="bibr" rid="B30-cancers-11-00844">30</xref>,<xref ref-type="bibr" rid="B31-cancers-11-00844">31</xref>]. Whether these are significant overestimates remains to be determined. Papillary (including follicular variant) thyroid cancer represents 56–60%, while follicular pathology accounts for 25–45% of reported cancers [<xref ref-type="bibr" rid="B51-cancers-11-00844">51</xref>,<xref ref-type="bibr" rid="B52-cancers-11-00844">52</xref>]. Medullary thyroid cancer is not felt to be associated with <italic>PTEN</italic> mutations. </p>
<p>The prevalence of <italic>PTEN</italic> mutations in unselected individuals presenting with differentiated thyroid cancer appears to be low, with only two mutations found in 259 individuals in one study. Both patients had follicular thyroid cancer and other features of PHTS such as macrocephaly. Among follicular thyroid cancer cases 2/42 harbored <italic>PTEN</italic> mutations [<xref ref-type="bibr" rid="B53-cancers-11-00844">53</xref>]. Another study found no <italic>PTEN</italic> mutations in women presenting with both primary breast and thyroid cancers [<xref ref-type="bibr" rid="B54-cancers-11-00844">54</xref>]. </p>
</sec>
<sec id="sec2dot7-cancers-11-00844">
<title>2.7. Renal Cell Carcinoma</title>
<p>The risk for renal cell carcinoma (RCC) was initially suggested to be increased in CS based on several case reports [<xref ref-type="bibr" rid="B55-cancers-11-00844">55</xref>,<xref ref-type="bibr" rid="B56-cancers-11-00844">56</xref>]. More recent case series of patients with <italic>PTEN</italic> mutations reported RCC in 5% of 107 clinically tested adults and 3–6.7% of adults who had research testing [<xref ref-type="bibr" rid="B6-cancers-11-00844">6</xref>,<xref ref-type="bibr" rid="B19-cancers-11-00844">19</xref>]. Two studies recently projected the lifetime risk for RCC in individuals with <italic>PTEN</italic> mutations to be approximately 34%, although these were based on small numbers of cases and may be an overestimate reflecting ascertainment bias [<xref ref-type="bibr" rid="B30-cancers-11-00844">30</xref>,<xref ref-type="bibr" rid="B31-cancers-11-00844">31</xref>]. In another series, four of 24 (16.7%) patients with CS were found to have a total of five RCC, although none had a family history of RCC [<xref ref-type="bibr" rid="B57-cancers-11-00844">57</xref>]. Loss of heterozygosity for <italic>PTEN</italic> was shown for four of the five tumors. Among eight PHTS patients with RCC, Mester et al. found papillary histology in six and chromophobe histology in two [<xref ref-type="bibr" rid="B58-cancers-11-00844">58</xref>]. Immunohistochemistry showed complete loss of <italic>PTEN</italic> staining in all six papillary tumors and patchy positivity in one of the chromophobe tumors. Germline <italic>PTEN</italic> mutations are rare among individuals with non-syndromic hereditary RCC [<xref ref-type="bibr" rid="B57-cancers-11-00844">57</xref>].</p>
</sec>
</sec>
<sec id="sec3-cancers-11-00844">
<title>3. Benign Disease</title>
<p>As noted above, individuals with germline <italic>PTEN</italic> mutations are at risk for a range on non-malignant disease. The actual prevalence of most of these in PHTS patients, however, is difficult to determine.</p>
<sec id="sec3dot1-cancers-11-00844">
<title>3.1. Brain Lesions</title>
<p>There are limited data on the prevalence of developmental delay and mental retardation (MR/DD) among individuals with <italic>PTEN</italic> mutations. The prevalence does seem to be increased over the general population rate of 3%, however, with MR/DD reported in 12% [<xref ref-type="bibr" rid="B29-cancers-11-00844">29</xref>] and 15–20% [<xref ref-type="bibr" rid="B59-cancers-11-00844">59</xref>] of cases in the literature, and in 17% of 110 mutation-positive patients who underwent clinical testing [<xref ref-type="bibr" rid="B6-cancers-11-00844">6</xref>]. It has been reported that 15–20% of patients with BRRS have mental retardation and an additional 50% may have motor and speech delays but normal adult intelligence [<xref ref-type="bibr" rid="B59-cancers-11-00844">59</xref>]. There is a broad range of manifestation, from normal intelligence (in most), to mild-significant developmental delays/MR, to autism spectrum disorders.</p>
<p>Based on cases reported in the literature, macrocephaly (defined as a head circumference greater than the 97th percentile) was initially reported to be present in 40% of CS patients. It has since been found in 80–100% of patients with <italic>PTEN</italic> mutations whose head circumference had been measured, [<xref ref-type="bibr" rid="B6-cancers-11-00844">6</xref>,<xref ref-type="bibr" rid="B19-cancers-11-00844">19</xref>,<xref ref-type="bibr" rid="B21-cancers-11-00844">21</xref>,<xref ref-type="bibr" rid="B60-cancers-11-00844">60</xref>,<xref ref-type="bibr" rid="B61-cancers-11-00844">61</xref>]. Macrocephaly is also seen in the majority of BRRS patients, but it is also one of the few diagnostic criteria for the condition so it would be expected to be frequently seen [<xref ref-type="bibr" rid="B59-cancers-11-00844">59</xref>]. Hansen-Kiss et al. found macrocephaly in 46 of 47 (98%) pediatric patients with <italic>PTEN</italic> mutations in their study [<xref ref-type="bibr" rid="B62-cancers-11-00844">62</xref>]. Vanderver et al. reported the brain MRI findings (including enlarged perivascular spaces and multifocal periventricular white matter abnormalities) in a cohort of 23 patients with <italic>PTEN</italic> mutations and macrocephaly [<xref ref-type="bibr" rid="B63-cancers-11-00844">63</xref>], while Ciaccio et al. found various brain abnormalities in 75% of pediatric <italic>PTEN</italic> mutation carriers who had imaging [<xref ref-type="bibr" rid="B64-cancers-11-00844">64</xref>] and Hansen-Kiss et al. found a range of abnormalities in 53% of 17 children with <italic>PTEN</italic> mutations who had brain imaging [<xref ref-type="bibr" rid="B62-cancers-11-00844">62</xref>]. Balci et al. reported on nine patients with <italic>PTEN</italic> mutations and white matter changes on brain MRI who presented with a range of developmental phenotypes [<xref ref-type="bibr" rid="B65-cancers-11-00844">65</xref>].</p>
<p>Germline mutations in <italic>PTEN</italic> also cause a subset of patients with both autism spectrum disorders (ASD) and macrocephaly, with patients with the largest head sizes being more likely to have a mutation [<xref ref-type="bibr" rid="B66-cancers-11-00844">66</xref>,<xref ref-type="bibr" rid="B67-cancers-11-00844">67</xref>,<xref ref-type="bibr" rid="B68-cancers-11-00844">68</xref>,<xref ref-type="bibr" rid="B69-cancers-11-00844">69</xref>,<xref ref-type="bibr" rid="B70-cancers-11-00844">70</xref>,<xref ref-type="bibr" rid="B71-cancers-11-00844">71</xref>,<xref ref-type="bibr" rid="B72-cancers-11-00844">72</xref>,<xref ref-type="bibr" rid="B73-cancers-11-00844">73</xref>]. In these reports <italic>PTEN</italic> mutations have been found in 1–27% of patients with ASD and macrocephaly, even in absence of other personal or family history suggestive of PHTS. Some evidence suggests that <italic>PTEN</italic> mutations retaining partial function may lead to milder phenotypes such as these [<xref ref-type="bibr" rid="B11-cancers-11-00844">11</xref>,<xref ref-type="bibr" rid="B12-cancers-11-00844">12</xref>,<xref ref-type="bibr" rid="B74-cancers-11-00844">74</xref>].</p>
</sec>
<sec id="sec3dot2-cancers-11-00844">
<title>3.2. Gastrointestinal Disease</title>
<p>Despite initial reports that colonic polyps were found in 40% of patients with CS, recent data has shown that polyps are found in up to 95% of adults with <italic>PTEN</italic> mutations who have undergone colonoscopy [<xref ref-type="bibr" rid="B36-cancers-11-00844">36</xref>,<xref ref-type="bibr" rid="B37-cancers-11-00844">37</xref>]. Polyp numbers can be few or numerous (even hundreds), may sometimes occur in childhood, and are distributed throughout the colon. The range of polyp types seen includes adenomas, ganglioneuromas, hamartomas, inflammatory polyps, leiomyomas, lipomas, and lymphoid polyps [<xref ref-type="bibr" rid="B36-cancers-11-00844">36</xref>,<xref ref-type="bibr" rid="B50-cancers-11-00844">50</xref>,<xref ref-type="bibr" rid="B75-cancers-11-00844">75</xref>,<xref ref-type="bibr" rid="B76-cancers-11-00844">76</xref>]. Hyperplastic polyps have also been seen, but they are common in the general population and have not been observed in all studies so the association with <italic>PTEN</italic> is unclear [<xref ref-type="bibr" rid="B36-cancers-11-00844">36</xref>,<xref ref-type="bibr" rid="B77-cancers-11-00844">77</xref>]. The majority of CS patients have multiple synchronous histologic types at colonoscopy. Among 603 patients with five or more colon polyps (including at least one hamartomatous or hyperplastic polyp), Ngeow et al. found germline mutations in known non-adenomatous polyposis genes in 13%, including <italic>PTEN</italic> mutations in 2.2% [<xref ref-type="bibr" rid="B78-cancers-11-00844">78</xref>]. Patients with ganglioneuromas, intramucosal lipomas, and/or those with three or more polyp types were more likely to harbor <italic>PTEN</italic> mutations [<xref ref-type="bibr" rid="B76-cancers-11-00844">76</xref>,<xref ref-type="bibr" rid="B79-cancers-11-00844">79</xref>]. Shaco-Levy et al. described a similar range of histologies among the polyps seen in 13 patients with CS [<xref ref-type="bibr" rid="B80-cancers-11-00844">80</xref>]. Henderson et al. suggested that eosinophilic gastrointestinal disorders may be more common in children with <italic>PTEN</italic> mutations [<xref ref-type="bibr" rid="B81-cancers-11-00844">81</xref>].</p>
<p>The esophagus in PHTS is characterized by glycogenic acanthosis [<xref ref-type="bibr" rid="B82-cancers-11-00844">82</xref>]. One or several such lesions may occasionally be observed in unaffected individuals, but numerous and diffuse lesions were seen in the majority (80% or more) of CS patients in one study [<xref ref-type="bibr" rid="B77-cancers-11-00844">77</xref>]. Although one group has recommended that diffuse esophageal glycogenic acanthosis combined with colonic polyposis should be considered pathognomonic for CS, this has not been incorporated into the NCCN diagnostic criteria [<xref ref-type="bibr" rid="B83-cancers-11-00844">83</xref>].</p>
<p>Upper gastrointestinal lesions are also seen in PHTS, with multiple hamartomatous polyps in the stomach, duodenum, and small bowel reported [<xref ref-type="bibr" rid="B34-cancers-11-00844">34</xref>,<xref ref-type="bibr" rid="B36-cancers-11-00844">36</xref>,<xref ref-type="bibr" rid="B77-cancers-11-00844">77</xref>,<xref ref-type="bibr" rid="B82-cancers-11-00844">82</xref>]. These included adenomas, hamartomas, and inflammatory and hyperplastic polyps (different from colonic hyperplastic polyps), as well as ganglioneuromas.</p>
</sec>
<sec id="sec3dot3-cancers-11-00844">
<title>3.3. Skin Lesions</title>
<p>A number of dermatologic lesions are common in PHTS. While initial reports (published at a time when dermatologic features were required to make a clinical diagnosis of Cowden syndrome) suggesting dermatologic lesions are present in almost 100% of CS patients are likely overestimates, it is clear that they are a common finding in individuals with <italic>PTEN</italic> mutations.</p>
<p>Among these, multiple trichilemmomas are most strongly indicative of a <italic>PTEN</italic> mutation. These can be seen on the face including the eyes, mouth, nose, and forehead [<xref ref-type="bibr" rid="B15-cancers-11-00844">15</xref>,<xref ref-type="bibr" rid="B48-cancers-11-00844">48</xref>,<xref ref-type="bibr" rid="B84-cancers-11-00844">84</xref>,<xref ref-type="bibr" rid="B85-cancers-11-00844">85</xref>,<xref ref-type="bibr" rid="B86-cancers-11-00844">86</xref>,<xref ref-type="bibr" rid="B87-cancers-11-00844">87</xref>], as well as the neck, axillae, and hand [<xref ref-type="bibr" rid="B88-cancers-11-00844">88</xref>,<xref ref-type="bibr" rid="B89-cancers-11-00844">89</xref>]. The prevalence of trichilemmomas in individuals with a confirmed <italic>PTEN</italic> mutation ranges from 6 to 25% in large case series, with some patients presenting under 18 years of age [<xref ref-type="bibr" rid="B3-cancers-11-00844">3</xref>,<xref ref-type="bibr" rid="B6-cancers-11-00844">6</xref>,<xref ref-type="bibr" rid="B19-cancers-11-00844">19</xref>,<xref ref-type="bibr" rid="B36-cancers-11-00844">36</xref>]. Trichilemmomas are clinically indistinguishable from trichoepitheliomas, fibrofolliculomas, and other benign skin lesions and thus require histopathology to confirm a diagnosis [<xref ref-type="bibr" rid="B85-cancers-11-00844">85</xref>,<xref ref-type="bibr" rid="B86-cancers-11-00844">86</xref>,<xref ref-type="bibr" rid="B90-cancers-11-00844">90</xref>,<xref ref-type="bibr" rid="B91-cancers-11-00844">91</xref>].</p>
<p>Acral keratoses, located on the palmoplantar surfaces and dorsal hands/feet, have been repeatedly reported in both children and adults with PHTS [<xref ref-type="bibr" rid="B15-cancers-11-00844">15</xref>,<xref ref-type="bibr" rid="B29-cancers-11-00844">29</xref>,<xref ref-type="bibr" rid="B48-cancers-11-00844">48</xref>,<xref ref-type="bibr" rid="B88-cancers-11-00844">88</xref>,<xref ref-type="bibr" rid="B92-cancers-11-00844">92</xref>,<xref ref-type="bibr" rid="B93-cancers-11-00844">93</xref>,<xref ref-type="bibr" rid="B94-cancers-11-00844">94</xref>]. Acral keratoses have been noted in both pediatric and adult populations of <italic>PTEN</italic> mutation carriers, but further studies are needed to define the age of onset and penetrance [<xref ref-type="bibr" rid="B19-cancers-11-00844">19</xref>,<xref ref-type="bibr" rid="B36-cancers-11-00844">36</xref>,<xref ref-type="bibr" rid="B93-cancers-11-00844">93</xref>,<xref ref-type="bibr" rid="B95-cancers-11-00844">95</xref>]. Some case reports observed keratoses appearing on non-acral sites as well [<xref ref-type="bibr" rid="B15-cancers-11-00844">15</xref>,<xref ref-type="bibr" rid="B48-cancers-11-00844">48</xref>]. At this time further studies are needed to determine the penetrance and age of onset of acral keratoses in PHTS, as well as to determine if they are more common in non-acral sites as well.</p>
<p>Sclerotic fibromas of the skin, which are rare in the general population, have been reported in a number of case series of patients with a clinical diagnoses of Cowden syndrome prior to the identification of the <italic>PTEN</italic> gene, and in individual case reports of patients with mutations [<xref ref-type="bibr" rid="B15-cancers-11-00844">15</xref>,<xref ref-type="bibr" rid="B96-cancers-11-00844">96</xref>,<xref ref-type="bibr" rid="B97-cancers-11-00844">97</xref>,<xref ref-type="bibr" rid="B98-cancers-11-00844">98</xref>]. Among clinically diagnosed Cowden syndrome patients the prevalence of oral fibromas ranges between 14 and 76% [<xref ref-type="bibr" rid="B15-cancers-11-00844">15</xref>,<xref ref-type="bibr" rid="B29-cancers-11-00844">29</xref>]. Although more common in the general population than sclerotic fibromas, the incidence of oral fibromas in the general population is not well defined. Further studies are needed in individuals with <italic>PTEN</italic> mutations to characterize the prevalence and natural history of both skin and oral fibromas. </p>
<p>Lipomas are included in the clinical diagnostic criteria for both BRRS and CS. In a prospective cohort of 43 clinically and/or genetically diagnosed BRRS cases compared to 37 Cowden syndrome families, the features of lipomas and vascular abnormalities were more commonly observed in BRRS or BRRS/Cowden syndrome overlap families [<xref ref-type="bibr" rid="B5-cancers-11-00844">5</xref>]. The presence of multiple lipomas in an individual in the general population is rare but this has been reported in several small and large case series of individuals with a <italic>PTEN</italic> mutation. [<xref ref-type="bibr" rid="B6-cancers-11-00844">6</xref>,<xref ref-type="bibr" rid="B15-cancers-11-00844">15</xref>,<xref ref-type="bibr" rid="B36-cancers-11-00844">36</xref>,<xref ref-type="bibr" rid="B48-cancers-11-00844">48</xref>,<xref ref-type="bibr" rid="B55-cancers-11-00844">55</xref>,<xref ref-type="bibr" rid="B88-cancers-11-00844">88</xref>,<xref ref-type="bibr" rid="B91-cancers-11-00844">91</xref>,<xref ref-type="bibr" rid="B93-cancers-11-00844">93</xref>,<xref ref-type="bibr" rid="B99-cancers-11-00844">99</xref>,<xref ref-type="bibr" rid="B100-cancers-11-00844">100</xref>,<xref ref-type="bibr" rid="B101-cancers-11-00844">101</xref>,<xref ref-type="bibr" rid="B102-cancers-11-00844">102</xref>,<xref ref-type="bibr" rid="B103-cancers-11-00844">103</xref>].</p>
<p>Mucocutaneous neuromas (hamartoma of the peripheral nerve sheath) have been reported on the face, hands, shins, and back in numerous patients with PHTS, with Starink et al. (reporting before the identification of the <italic>PTEN</italic> gene) finding them in more than half of their clinically-diagnosed patients by age 18 [<xref ref-type="bibr" rid="B15-cancers-11-00844">15</xref>,<xref ref-type="bibr" rid="B48-cancers-11-00844">48</xref>,<xref ref-type="bibr" rid="B101-cancers-11-00844">101</xref>,<xref ref-type="bibr" rid="B104-cancers-11-00844">104</xref>]. At this time further studies are needed to determine the prevalence and clinical features of neuromas seen in PHTS.</p>
<p>Oral papillomas, seen on the lips, tongue, buccal mucosa, and gingivae, are common in PHTS, although the florid papillomatosis shown in some publications is rare [<xref ref-type="bibr" rid="B15-cancers-11-00844">15</xref>,<xref ref-type="bibr" rid="B29-cancers-11-00844">29</xref>,<xref ref-type="bibr" rid="B48-cancers-11-00844">48</xref>,<xref ref-type="bibr" rid="B84-cancers-11-00844">84</xref>,<xref ref-type="bibr" rid="B88-cancers-11-00844">88</xref>,<xref ref-type="bibr" rid="B89-cancers-11-00844">89</xref>,<xref ref-type="bibr" rid="B91-cancers-11-00844">91</xref>,<xref ref-type="bibr" rid="B92-cancers-11-00844">92</xref>,<xref ref-type="bibr" rid="B103-cancers-11-00844">103</xref>,<xref ref-type="bibr" rid="B105-cancers-11-00844">105</xref>,<xref ref-type="bibr" rid="B106-cancers-11-00844">106</xref>]. They typically present by the second decade of life and are usually asymptomatic, in contrast to neuromas [<xref ref-type="bibr" rid="B15-cancers-11-00844">15</xref>,<xref ref-type="bibr" rid="B84-cancers-11-00844">84</xref>,<xref ref-type="bibr" rid="B88-cancers-11-00844">88</xref>,<xref ref-type="bibr" rid="B89-cancers-11-00844">89</xref>,<xref ref-type="bibr" rid="B93-cancers-11-00844">93</xref>,<xref ref-type="bibr" rid="B101-cancers-11-00844">101</xref>,<xref ref-type="bibr" rid="B104-cancers-11-00844">104</xref>]. </p>
<p>While benign pigmentation of the genitals is reported in up to 15% of males in the general population [<xref ref-type="bibr" rid="B107-cancers-11-00844">107</xref>], their prevalence is clearly increased in males with <italic>PTEN</italic> mutations. In one large cohort, 48% of males with either a clinical diagnosis or a <italic>PTEN</italic> mutation had significant penile freckling, while in another study, 53% of male <italic>PTEN</italic> mutation carriers had this finding [<xref ref-type="bibr" rid="B6-cancers-11-00844">6</xref>,<xref ref-type="bibr" rid="B19-cancers-11-00844">19</xref>]. Hansen-Kiss et al. found penile freckling in 12/29 (41%) of boys with <italic>PTEN</italic> mutations, the youngest at 15 months of age [<xref ref-type="bibr" rid="B62-cancers-11-00844">62</xref>].</p>
<p>Vascular (venous or arterial) anomalies are reportedly common in BRRS and CS, particularly in patients with a BRRS diagnosis. A number of case reports support the association of arteriovenous malformations in clinically diagnosed BRRS patients [<xref ref-type="bibr" rid="B108-cancers-11-00844">108</xref>,<xref ref-type="bibr" rid="B109-cancers-11-00844">109</xref>,<xref ref-type="bibr" rid="B110-cancers-11-00844">110</xref>,<xref ref-type="bibr" rid="B111-cancers-11-00844">111</xref>]. Among 20 CS patients undergoing brain MRI, Lok et al. noted venous angiomas in five and cavernous angiomas in two [<xref ref-type="bibr" rid="B26-cancers-11-00844">26</xref>]. Tan et al. reported on the vascular anomalies seen in a cohort of 23 patients with <italic>PTEN</italic> mutations, while Kurek et al., reporting on a cohort of patients with known or suspected <italic>PTEN</italic> mutations, noted a distinctive lesions they designated as a <italic>PTEN</italic> hamartoma of soft tissue [<xref ref-type="bibr" rid="B21-cancers-11-00844">21</xref>,<xref ref-type="bibr" rid="B112-cancers-11-00844">112</xref>]. Smaller case series have specifically reported hemangiomas and cavernous hemangiomas in both children and adults with <italic>PTEN</italic> mutations [<xref ref-type="bibr" rid="B62-cancers-11-00844">62</xref>,<xref ref-type="bibr" rid="B94-cancers-11-00844">94</xref>,<xref ref-type="bibr" rid="B101-cancers-11-00844">101</xref>,<xref ref-type="bibr" rid="B102-cancers-11-00844">102</xref>]. Pimpalwar et al. reported on the natural history and management of fast flow vascular anomalies in four patients [<xref ref-type="bibr" rid="B113-cancers-11-00844">113</xref>]. In the general population, certain subtypes of hemangioma are sporadic and common in children or adults [<xref ref-type="bibr" rid="B114-cancers-11-00844">114</xref>]. Thus, further studies are needed on the prevalence of vascular lesions in PHTS.</p>
<p>Testicular lipomas have only been noted in PHTS since 2003, being first reported in a 39 year-old male with multiple fat-containing testicular hamartomas [<xref ref-type="bibr" rid="B115-cancers-11-00844">115</xref>]. Since then, Woodhouse et al. reported findings from testicular ultrasound in a series of eight males (ages 16 to 58) with documented <italic>PTEN</italic> mutations, finding multiple, bilateral hyperechoic lesions in all but the youngest patient [<xref ref-type="bibr" rid="B116-cancers-11-00844">116</xref>,<xref ref-type="bibr" rid="B117-cancers-11-00844">117</xref>]. Biopsies from four of the patients confirmed lipomas. Subsequently, multiple other cases of testicular lipomas in males with CS or BRRS have been reported [<xref ref-type="bibr" rid="B118-cancers-11-00844">118</xref>,<xref ref-type="bibr" rid="B119-cancers-11-00844">119</xref>,<xref ref-type="bibr" rid="B120-cancers-11-00844">120</xref>,<xref ref-type="bibr" rid="B121-cancers-11-00844">121</xref>,<xref ref-type="bibr" rid="B122-cancers-11-00844">122</xref>]. Testicular lipomas are very rare in the general population in absence of testicular neoplasia [<xref ref-type="bibr" rid="B117-cancers-11-00844">117</xref>], with Harper et al. finding only one case in a Medline search from 1970 to 2001 [<xref ref-type="bibr" rid="B123-cancers-11-00844">123</xref>]. Although their prevalence in males with <italic>PTEN</italic> mutations is unknown, the presence of multiple testicular lipomas has been added to the clinical diagnostic criteria for CS/PHTS [<xref ref-type="bibr" rid="B17-cancers-11-00844">17</xref>].</p>
</sec>
<sec id="sec3dot4-cancers-11-00844">
<title>3.4. Thyroid Disease </title>
<p>Benign thyroid disease is common in PHTS, with thyroid nodules, adenoma, or goiter reported in 30–68% of adults and 2–14% of children with <italic>PTEN</italic> mutations [<xref ref-type="bibr" rid="B6-cancers-11-00844">6</xref>,<xref ref-type="bibr" rid="B19-cancers-11-00844">19</xref>]. Tan et al. reported a prevalence of 3–21% specifically for Hashimoto thyroiditis in individuals with <italic>PTEN</italic> mutations [<xref ref-type="bibr" rid="B19-cancers-11-00844">19</xref>]. Hall et al. reviewed the thyroid findings in 181 CS patients reported in the literature, with their inherent ascertainment and publication biases, and found thyroid disease reported in 53% of patients, with 80% of these requiring surgical management [<xref ref-type="bibr" rid="B124-cancers-11-00844">124</xref>]. It should be noted that almost 38% of these patients did not have genetic testing to confirm the presence of a <italic>PTEN</italic> mutation. Thyroid lesions are very common in the general population, which complicates efforts to determine their prevalence in PHTS. The prevalence of thyroid nodules in the general population ranges from 2 to 6% on physical exam to 19–35% on ultrasound to as high as 65% in autopsy series [<xref ref-type="bibr" rid="B125-cancers-11-00844">125</xref>]. Multinodular goiter is found in about 4% of the population, [<xref ref-type="bibr" rid="B126-cancers-11-00844">126</xref>] while Hashimoto’s thyroiditis occurs in 2% [<xref ref-type="bibr" rid="B127-cancers-11-00844">127</xref>].</p>
<p>Hansen-Kiss et al. found abnormal thyroid imaging (cysts, nodules and goiter) in 26% of their series of 47 pediatric patients with <italic>PTEN</italic> mutations [<xref ref-type="bibr" rid="B62-cancers-11-00844">62</xref>]. Plamper, reporting on patients seen in a pediatric endocrine clinic, found thyroid abnormalities in 12 of 16 (75%) children with <italic>PTEN</italic> mutations in their series, with eight of them undergoing thyroidectomy [<xref ref-type="bibr" rid="B128-cancers-11-00844">128</xref>]. Pathology varied from nodular goiter, follicular adenoma and autoimmune disease to papillary microcarcinoma in a six-year-old boy and follicular carcinoma in a 13-year-old girl. </p>
<p>There are limited data on the clinical features and pathology of thyroid nodules in <italic>PTEN</italic> mutation carriers. One review of thyroidectomy specimens from 20 individuals found that all had multiple findings, most commonly multinodular goiter (75%), which was often seen along with thyroiditis (55%) [<xref ref-type="bibr" rid="B52-cancers-11-00844">52</xref>]. Another study of the thyroid pathology from 25 individuals with <italic>PTEN</italic> mutations had similar findings [<xref ref-type="bibr" rid="B129-cancers-11-00844">129</xref>]. A pediatric study found thyroid nodules at as young as age 6 [<xref ref-type="bibr" rid="B130-cancers-11-00844">130</xref>]. It is important to note the ascertainment biases in these studies, however, since most were evaluating individuals who presented with significant and overt thyroid disease, and the frequency and clinical presentation in unselected mutation carriers is unknown.</p>
</sec>
<sec id="sec3dot5-cancers-11-00844">
<title>3.5. Other Benign Diseases</title>
<p>Other benign lesions such as fibrocystic and other benign breast diseases, uterine fibroids, and genito-urinary malformations were initially included in the clinical diagnostic criteria for CS. However, there is insufficient evidence to show that they are more common among individuals with <italic>PTEN</italic> mutations than in the general population (in which fibrocystic breast disease and uterine fibroids in particular are very common), and they have been dropped from the clinical diagnostic criteria [<xref ref-type="bibr" rid="B16-cancers-11-00844">16</xref>,<xref ref-type="bibr" rid="B17-cancers-11-00844">17</xref>]. While a range of other breast lesions (sometimes quite complex) have been reported in case reports or small series of women with clinical or molecular diagnoses of Cowden syndrome, there are no good data on unselected patient populations [<xref ref-type="bibr" rid="B131-cancers-11-00844">131</xref>,<xref ref-type="bibr" rid="B132-cancers-11-00844">132</xref>]. </p>
<p>While more data are needed, a growing number of reports suggest possible immune system dysregulation in some individuals with germline <italic>PTEN</italic> mutations, as shown in mouse models [<xref ref-type="bibr" rid="B133-cancers-11-00844">133</xref>,<xref ref-type="bibr" rid="B134-cancers-11-00844">134</xref>,<xref ref-type="bibr" rid="B135-cancers-11-00844">135</xref>,<xref ref-type="bibr" rid="B136-cancers-11-00844">136</xref>,<xref ref-type="bibr" rid="B137-cancers-11-00844">137</xref>]. In addition, there is evidence for the role of <italic>PTEN</italic> in metabolic regulation and for a form of constitutive insulin sensitivity in some individuals with <italic>PTEN</italic> mutations [<xref ref-type="bibr" rid="B138-cancers-11-00844">138</xref>,<xref ref-type="bibr" rid="B139-cancers-11-00844">139</xref>,<xref ref-type="bibr" rid="B140-cancers-11-00844">140</xref>,<xref ref-type="bibr" rid="B141-cancers-11-00844">141</xref>].</p>
</sec>
</sec>
<sec id="sec4-cancers-11-00844" sec-type="conclusions">
<title>4. Conclusions</title>
<p>As has been shown, our understanding of the clinical and molecular features of <italic>PTEN</italic> hamartoma tumor syndrome continues to evolve. As with many rare conditions, it has been difficult to obtain data on substantial numbers of patients with PHTS. The larger patient cohorts that have been assembled suffer from significant ascertainment bias since most of the patients were tested specifically because they presented with significant clinical features of PHTS. To date, no large cohort study has been published on mutation carriers who are relatives of the probands who were initially tested (which would help reduce ascertainment bias). Unfortunately, it is unlikely that such a cohort could be assembled, and thus we must rely on the data that are available. In recent years, various publications have improved on our understanding of the prevalence of <italic>PTEN</italic> mutations, macrocephaly, and colon disease in particular in PHTS patients, and have added testicular lipomatosis and possibly immunologic problems to the PHTS phenotypic spectrum. At the same time, we have seen that the data do not support the inclusion of previously long-held features such as fibrocystic breast, uterine fibroid, and genito-urinary malformations. Over time we can expect to see further clarification of the phenotypes of this fascinating set of disorders.</p>
</sec>
</body>
<back>
<notes>
<title>Funding</title>
<p>This research received no external funding.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-cancers-11-00844">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lloyd</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Denis</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Cowden’s disease: A possible new symptom complex with multiple system involvement</article-title>
<source/>Ann. Intern. Med.
          <year>1963</year>
<volume>58</volume>
<fpage>136</fpage>
<lpage>142</lpage>
<pub-id pub-id-type="doi">10.7326/0003-4819-58-1-136</pub-id>
<pub-id pub-id-type="pmid">13931122</pub-id>
</element-citation>
</ref>
<ref id="B2-cancers-11-00844">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nelen</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>van Staveren</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Peeters</surname>
<given-names>E.A.J.</given-names>
</name>
<name>
<surname>Ben Hassel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gorlin</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Hamm</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lindboe</surname>
<given-names>C.F.</given-names>
</name>
<name>
<surname>Fryns</surname>
<given-names>J.-P.</given-names>
</name>
<name>
<surname>Sijmons</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Woods</surname>
<given-names>D.G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Germline mutations in the <italic>PTEN</italic>/<italic>MMAC1</italic> gene in patients with Cowden disease</article-title>
<source/>Hum. Mol. Genet.
          <year>1997</year>
<volume>6</volume>
<fpage>1383</fpage>
<lpage>1387</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/6.8.1383</pub-id>
<pub-id pub-id-type="pmid">9259288</pub-id>
</element-citation>
</ref>
<ref id="B3-cancers-11-00844">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liaw</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Marsh</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dahia</surname>
<given-names>P.L.M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.I.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Bose</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Call</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Tsou</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Peacocke</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Germline mutations of the <italic>PTEN</italic> gene in Cowden disease, an inherited breast and thyroid cancer syndrome</article-title>
<source/>Nat. Genet.
          <year>1997</year>
<volume>16</volume>
<fpage>64</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.1038/ng0597-64</pub-id>
<pub-id pub-id-type="pmid">9140396</pub-id>
</element-citation>
</ref>
<ref id="B4-cancers-11-00844">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gorlin</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>M.M.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Condon</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>B.A.</given-names>
</name>
</person-group>
<article-title>Bannayan-Riley-Ruvalcaba syndrome</article-title>
<source/>Am. J. Med. Genet.
          <year>1992</year>
<volume>44</volume>
<fpage>307</fpage>
<lpage>314</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.1320440309</pub-id>
<pub-id pub-id-type="pmid">1336932</pub-id>
</element-citation>
</ref>
<ref id="B5-cancers-11-00844">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marsh</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Kum</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Lunetta</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Gorlin</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>S.F.</given-names>
</name>
<name>
<surname>Bodurtha</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Crowe</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Curtis</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Dazouki</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title><italic>PTEN</italic> mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome</article-title>
<source/>Hum. Mol. Genet.
          <year>1999</year>
<volume>8</volume>
<fpage>1461</fpage>
<lpage>1472</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/8.8.1461</pub-id>
<pub-id pub-id-type="pmid">10400993</pub-id>
</element-citation>
</ref>
<ref id="B6-cancers-11-00844">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pilarski</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Stephens</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Noss</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Prior</surname>
<given-names>T.W.</given-names>
</name>
</person-group>
<article-title>Predicting <italic>PTEN</italic> mutations: An evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features</article-title>
<source/>J. Med. Genet.
          <year>2011</year>
<volume>48</volume>
<fpage>505</fpage>
<lpage>512</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2011.088807</pub-id>
<pub-id pub-id-type="pmid">21659347</pub-id>
</element-citation>
</ref>
<ref id="B7-cancers-11-00844">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hendriks</surname>
<given-names>Y.M.</given-names>
</name>
<name>
<surname>Verhallen</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>van der Smagt</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Kant</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Hilhorst</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hoefsloot</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hansson</surname>
<given-names>K.B.</given-names>
</name>
<name>
<surname>van der Straaten</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Boutkan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Breuning</surname>
<given-names>M.H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Bannayan-Riley-Ruvalcaba syndrome: Further delineation of the phenotype and management of <italic>PTEN</italic> mutation-positive cases</article-title>
<source/>Fam. Cancer
          <year>2003</year>
<volume>2</volume>
<fpage>79</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="doi">10.1023/A:1025713815924</pub-id>
<pub-id pub-id-type="pmid">14574156</pub-id>
</element-citation>
</ref>
<ref id="B8-cancers-11-00844">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Cowden syndrome</article-title>
<source/>J. Genet. Couns.
          <year>1997</year>
<volume>6</volume>
<fpage>181</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="doi">10.1023/A:1025664119494</pub-id>
<pub-id pub-id-type="pmid">26142096</pub-id>
</element-citation>
</ref>
<ref id="B9-cancers-11-00844">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Celebi</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Tsou</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>F.F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ping</surname>
<given-names>X.L.</given-names>
</name>
<name>
<surname>Lebwohl</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Kezis</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Peacocke</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Phenotypic findings of Cowden syndrome and Bannayan-Zonana syndrome in a family associated with a single germline mutation in <italic>PTEN</italic></article-title>
<source/>J. Med. Genet.
          <year>1999</year>
<volume>36</volume>
<fpage>360</fpage>
<lpage>364</lpage>
<pub-id pub-id-type="pmid">10353779</pub-id>
</element-citation>
</ref>
<ref id="B10-cancers-11-00844">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zori</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>Marsh</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Marliss</surname>
<given-names>E.B.</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Germline <italic>PTEN</italic> mutation in a family with Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome</article-title>
<source/>Am. J. Med. Genet.
          <year>1998</year>
<volume>80</volume>
<fpage>399</fpage>
<lpage>402</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(19981204)80:4&lt;399::AID-AJMG18&gt;3.0.CO;2-O</pub-id>
<pub-id pub-id-type="pmid">9856571</pub-id>
</element-citation>
</ref>
<ref id="B11-cancers-11-00844">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leslie</surname>
<given-names>N.R.</given-names>
</name>
<name>
<surname>Longy</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Inherited <italic>PTEN</italic> mutations and the prediction of phenotype</article-title>
<source/>Semin. Cell Dev. Biol.
          <year>2016</year>
<volume>52</volume>
<fpage>30</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1016/j.semcdb.2016.01.030</pub-id>
<pub-id pub-id-type="pmid">26827793</pub-id>
</element-citation>
</ref>
<ref id="B12-cancers-11-00844">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spinelli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Black</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>Eickholt</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Leslie</surname>
<given-names>N.R.</given-names>
</name>
</person-group>
<article-title>Functionally distinct groups of inherited <italic>PTEN</italic> mutations in autism and tumour syndromes</article-title>
<source/>J. Med. Genet.
          <year>2015</year>
<volume>52</volume>
<fpage>128</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="doi">10.1136/jmedgenet-2014-102803</pub-id>
<pub-id pub-id-type="pmid">25527629</pub-id>
</element-citation>
</ref>
<ref id="B13-cancers-11-00844">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freeman</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lesche</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kertesz</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Groszer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Martinez-Diaz</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Rozengurt</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic background controls tumor development in <italic>PTEN</italic>-deficient mice</article-title>
<source/>Cancer Res.
          <year>2006</year>
<volume>66</volume>
<fpage>6492</fpage>
<lpage>6496</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-4143</pub-id>
<pub-id pub-id-type="pmid">16818619</pub-id>
</element-citation>
</ref>
<ref id="B14-cancers-11-00844">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nelen</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Padberg</surname>
<given-names>G.W.</given-names>
</name>
<name>
<surname>Peeters</surname>
<given-names>E.A.J.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>A.Y.</given-names>
</name>
<name>
<surname>van den Helm</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Frants</surname>
<given-names>R.R.</given-names>
</name>
<name>
<surname>Coulon</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>van Reen</surname>
<given-names>M.M.M.</given-names>
</name>
<name>
<surname>Easton</surname>
<given-names>D.F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Localization of the gene for Cowden disease to 10q22-23</article-title>
<source/>Nat. Genet.
          <year>1996</year>
<volume>13</volume>
<fpage>114</fpage>
<lpage>116</lpage>
<pub-id pub-id-type="doi">10.1038/ng0596-114</pub-id>
<pub-id pub-id-type="pmid">8673088</pub-id>
</element-citation>
</ref>
<ref id="B15-cancers-11-00844">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starink</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>van der Veen</surname>
<given-names>J.P.W.</given-names>
</name>
<name>
<surname>Arwert</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>de Waal</surname>
<given-names>L.P.</given-names>
</name>
<name>
<surname>de Lange</surname>
<given-names>G.G.</given-names>
</name>
<name>
<surname>Gille</surname>
<given-names>J.J.P.</given-names>
</name>
<name>
<surname>Eriksson</surname>
<given-names>A.W.</given-names>
</name>
</person-group>
<article-title>The Cowden syndrome: A clinical and genetic study in 21 patients</article-title>
<source/>Clin. Genet.
          <year>1986</year>
<volume>29</volume>
<fpage>222</fpage>
<lpage>233</lpage>
<pub-id pub-id-type="doi">10.1111/j.1399-0004.1986.tb00816.x</pub-id>
<pub-id pub-id-type="pmid">3698331</pub-id>
</element-citation>
</ref>
<ref id="B16-cancers-11-00844">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>The National Comprehensive Cancer Network (NCCN)</collab>
</person-group>
<article-title>The NCCN guidelines genetic/familial high-risk assessment: Breast and ovarian</article-title>
<source/>J. Natl. Compr. Cancer Netw.
          <year>2017</year>
<volume>15</volume>
<fpage>9</fpage>
<lpage>20</lpage>
</element-citation>
</ref>
<ref id="B17-cancers-11-00844">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pilarski</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Burt</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kohlman</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Pho</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shannon</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Swisher</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Cowden syndrome and the <italic>PTEN</italic> hamartoma tumor syndrome: Systematic review and revised diagnostic criteria</article-title>
<source/>J. Natl. Cancer Inst.
          <year>2013</year>
<volume>105</volume>
<fpage>1607</fpage>
<lpage>1616</lpage>
<pub-id pub-id-type="doi">10.1093/jnci/djt277</pub-id>
<pub-id pub-id-type="pmid">24136893</pub-id>
</element-citation>
</ref>
<ref id="B18-cancers-11-00844">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marsh</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Coulon</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Lunetta</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Rocca-Serra</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Dahia</surname>
<given-names>P.L.M.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liaw</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Caron</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Duboué</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>A.Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline <italic>PTEN</italic> mutation</article-title>
<source/>Hum. Mol. Genet.
          <year>1998</year>
<volume>7</volume>
<fpage>507</fpage>
<lpage>515</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/7.3.507</pub-id>
<pub-id pub-id-type="pmid">9467011</pub-id>
</element-citation>
</ref>
<ref id="B19-cancers-11-00844">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Mester</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Rybicki</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Milas</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pederson</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Remzi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Orloff</surname>
<given-names>M.S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A clinical scoring system for selection of patients for <italic>PTEN</italic> mutation testing is proposed on the basis of a prospective study of 3042 probands</article-title>
<source/>Am. J. Hum. Genet.
          <year>2011</year>
<volume>88</volume>
<fpage>42</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2010.11.013</pub-id>
<pub-id pub-id-type="pmid">21194675</pub-id>
</element-citation>
</ref>
<ref id="B20-cancers-11-00844">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mester</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Estimate of de novo mutation frequency in probands with <italic>PTEN</italic> hamartoma tumor syndrome</article-title>
<source/>Genet. Med.
          <year>2012</year>
<volume>14</volume>
<fpage>819</fpage>
<lpage>822</lpage>
<pub-id pub-id-type="doi">10.1038/gim.2012.51</pub-id>
<pub-id pub-id-type="pmid">22595938</pub-id>
</element-citation>
</ref>
<ref id="B21-cancers-11-00844">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>W.H.</given-names>
</name>
<name>
<surname>Baris</surname>
<given-names>H.N.</given-names>
</name>
<name>
<surname>Burrows</surname>
<given-names>P.E.</given-names>
</name>
<name>
<surname>Robson</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Alomari</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Mulliken</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Fishman</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Irons</surname>
<given-names>M.B.</given-names>
</name>
</person-group>
<article-title>The spectrum of vascular anomalies in patients with <italic>PTEN</italic> mutations: Implications for diagnosis and management</article-title>
<source/>J. Med. Genet.
          <year>2007</year>
<volume>44</volume>
<fpage>594</fpage>
<lpage>602</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2007.048934</pub-id>
<pub-id pub-id-type="pmid">17526801</pub-id>
</element-citation>
</ref>
<ref id="B22-cancers-11-00844">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riegert-Johnson</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Gleeson</surname>
<given-names>F.C.</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tholen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Youngborg</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bullock</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Boardman</surname>
<given-names>L.A.</given-names>
</name>
</person-group>
<article-title>Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients</article-title>
<source/>Hered. Cancer Clin. Pract.
          <year>2010</year>
<volume>8</volume>
<fpage>6</fpage>
<pub-id pub-id-type="doi">10.1186/1897-4287-8-6</pub-id>
<pub-id pub-id-type="pmid">20565722</pub-id>
</element-citation>
</ref>
<ref id="B23-cancers-11-00844">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Magnetic resonance characteristics of adult-onset Lhermitte-Duclos disease: An indicator for active cancer surveillance?</article-title>
<source/>Mol. Clin. Oncol.
          <year>2014</year>
<volume>2</volume>
<fpage>415</fpage>
<lpage>420</lpage>
<pub-id pub-id-type="doi">10.3892/mco.2014.258</pub-id>
<pub-id pub-id-type="pmid">24772310</pub-id>
</element-citation>
</ref>
<ref id="B24-cancers-11-00844">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>X.P.</given-names>
</name>
<name>
<surname>Marsh</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Morrison</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Chaudhury</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Maxwell</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Reifenberger</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Germline inactivation of <italic>PTEN</italic> and dysregulation of the phosphoinositol-3-kinase/AKT pathway cause human Lhermitte-Duclos disease in adults</article-title>
<source/>Am. J. Hum. Genet.
          <year>2003</year>
<volume>73</volume>
<fpage>1191</fpage>
<lpage>1198</lpage>
<pub-id pub-id-type="doi">10.1086/379382</pub-id>
<pub-id pub-id-type="pmid">14566704</pub-id>
</element-citation>
</ref>
<ref id="B25-cancers-11-00844">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robinson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>A.R.</given-names>
</name>
</person-group>
<article-title>Cowden disease and Lhermitte-Duclos disease: An update. Case report and review of the literature</article-title>
<source/>Neurosurg. Focus
          <year>2006</year>
<volume>20</volume>
<fpage>E6</fpage>
<pub-id pub-id-type="doi">10.3171/foc.2006.20.1.7</pub-id>
</element-citation>
</ref>
<ref id="B26-cancers-11-00844">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lok</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Viseux</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Avril</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Richard</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Gondry-Jouet</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Deramond</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Desfossez-Tribout</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Courtade</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Delaunay</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Piette</surname>
<given-names>F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brain magnetic resonance imaging in patients with Cowden syndrome</article-title>
<source/>Medicine
          <year>2005</year>
<volume>84</volume>
<fpage>129</fpage>
<lpage>136</lpage>
<pub-id pub-id-type="doi">10.1097/01.md.0000158792.24888.d2</pub-id>
<pub-id pub-id-type="pmid">15758842</pub-id>
</element-citation>
</ref>
<ref id="B27-cancers-11-00844">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yakubov</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ghoochani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Buslei</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Buchfelder</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Eyupoglu</surname>
<given-names>I.Y.</given-names>
</name>
<name>
<surname>Savaskan</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Hidden association of Cowden syndrome, <italic>PTEN</italic> mutation and meningioma frequency</article-title>
<source/>Oncoscience
          <year>2016</year>
<volume>3</volume>
<fpage>149</fpage>
<lpage>155</lpage>
<pub-id pub-id-type="pmid">27489861</pub-id>
</element-citation>
</ref>
<ref id="B28-cancers-11-00844">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brownstein</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bikowski</surname>
<given-names>J.B.</given-names>
</name>
</person-group>
<article-title>Cowden’s disease: A cutaneous marker of breast cancer</article-title>
<source/>Cancer
          <year>1978</year>
<volume>41</volume>
<fpage>2393</fpage>
<lpage>2398</lpage>
<pub-id pub-id-type="doi">10.1002/1097-0142(197806)41:6&lt;2393::AID-CNCR2820410644&gt;3.0.CO;2-K</pub-id>
<pub-id pub-id-type="pmid">657103</pub-id>
</element-citation>
</ref>
<ref id="B29-cancers-11-00844">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hanssen</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Fryns</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Cowden syndrome</article-title>
<source/>J. Med. Genet.
          <year>1995</year>
<volume>32</volume>
<fpage>117</fpage>
<lpage>119</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.32.2.117</pub-id>
<pub-id pub-id-type="pmid">7760320</pub-id>
</element-citation>
</ref>
<ref id="B30-cancers-11-00844">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bubien</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bonnet</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Brouste</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Hoppe</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Barouk-Simonet</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>David</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Edery</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bottani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Layet</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Caron</surname>
<given-names>O.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>High cumulative risks of cancer in patients with <italic>PTEN</italic> hamartoma tumour syndrome</article-title>
<source/>J. Med. Genet.
          <year>2013</year>
<volume>50</volume>
<fpage>255</fpage>
<lpage>263</lpage>
<pub-id pub-id-type="doi">10.1136/jmedgenet-2012-101339</pub-id>
<pub-id pub-id-type="pmid">23335809</pub-id>
</element-citation>
</ref>
<ref id="B31-cancers-11-00844">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Mester</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Ngeow</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rybicki</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Orloff</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Lifetime cancer risks in individuals with germline <italic>PTEN</italic> mutations</article-title>
<source/>Clin. Cancer Res.
          <year>2012</year>
<volume>18</volume>
<fpage>400</fpage>
<lpage>407</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-2283</pub-id>
<pub-id pub-id-type="pmid">22252256</pub-id>
</element-citation>
</ref>
<ref id="B32-cancers-11-00844">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fackenthal</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Marsh</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>B.G.</given-names>
</name>
<name>
<surname>Olopade</surname>
<given-names>O.I.</given-names>
</name>
</person-group>
<article-title>Male breast cancer in Cowden syndrome patients with germline <italic>PTEN</italic> mutations</article-title>
<source/>J. Med. Genet.
          <year>2001</year>
<volume>38</volume>
<fpage>159</fpage>
<lpage>164</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.38.3.159</pub-id>
<pub-id pub-id-type="pmid">11238682</pub-id>
</element-citation>
</ref>
<ref id="B33-cancers-11-00844">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagelstrom</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>Ford</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Reiser</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pickering</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Althof</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Sanger</surname>
<given-names>W.G.</given-names>
</name>
<name>
<surname>Coccia</surname>
<given-names>P.F.</given-names>
</name>
</person-group>
<article-title>Breast cancer and non-Hodgkin lymphoma in a young male with Cowden syndrome</article-title>
<source/>Pediatr. Blood Cancer
          <year>2016</year>
<volume>63</volume>
<fpage>544</fpage>
<lpage>546</lpage>
<pub-id pub-id-type="doi">10.1002/pbc.25796</pub-id>
<pub-id pub-id-type="pmid">26468640</pub-id>
</element-citation>
</ref>
<ref id="B34-cancers-11-00844">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schreibman</surname>
<given-names>I.R.</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Amos</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>McGarrity</surname>
<given-names>T.J.</given-names>
</name>
</person-group>
<article-title>The hamartomatous polyposis syndromes: A clinical and molecular review</article-title>
<source/>Am. J. Gastroenterol.
          <year>2005</year>
<volume>100</volume>
<fpage>476</fpage>
<lpage>490</lpage>
<pub-id pub-id-type="doi">10.1111/j.1572-0241.2005.40237.x</pub-id>
<pub-id pub-id-type="pmid">15667510</pub-id>
</element-citation>
</ref>
<ref id="B35-cancers-11-00844">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kato</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mizuki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kunihiro</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nagata</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tsukada</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Orikasa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Morinaga</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Cowden’s disease diagnosed through mucocutaneous lesions and gastrointestinal polyposis with recurrent hematochezia, unrevealed by initial diagnosis</article-title>
<source/>Intern. Med.
          <year>2000</year>
<volume>39</volume>
<fpage>559</fpage>
<lpage>563</lpage>
<pub-id pub-id-type="doi">10.2169/internalmedicine.39.559</pub-id>
<pub-id pub-id-type="pmid">10888212</pub-id>
</element-citation>
</ref>
<ref id="B36-cancers-11-00844">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heald</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mester</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rybicki</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Orloff</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of <italic>PTEN</italic> mutation carriers</article-title>
<source/>Gastroenterology
          <year>2010</year>
<volume>139</volume>
<fpage>1927</fpage>
<lpage>1933</lpage>
<pub-id pub-id-type="doi">10.1053/j.gastro.2010.06.061</pub-id>
<pub-id pub-id-type="pmid">20600018</pub-id>
</element-citation>
</ref>
<ref id="B37-cancers-11-00844">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stanich</surname>
<given-names>P.P.</given-names>
</name>
<name>
<surname>Owens</surname>
<given-names>V.L.</given-names>
</name>
<name>
<surname>Sweetser</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Khambatta</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Smyrk</surname>
<given-names>T.C.</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Goetz</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Patnaik</surname>
<given-names>M.M.</given-names>
</name>
</person-group>
<article-title>Colonic polyposis and neoplasia in Cowden syndrome</article-title>
<source/>Mayo Clin. Proc.
          <year>2011</year>
<volume>86</volume>
<fpage>489</fpage>
<lpage>492</lpage>
<pub-id pub-id-type="doi">10.4065/mcp.2010.0816</pub-id>
<pub-id pub-id-type="pmid">21628613</pub-id>
</element-citation>
</ref>
<ref id="B38-cancers-11-00844">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Thihli</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Palma</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Marcus</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Cesari</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kushner</surname>
<given-names>Y.B.</given-names>
</name>
<name>
<surname>Barkun</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Foulkes</surname>
<given-names>W.D.</given-names>
</name>
</person-group>
<article-title>A case of Cowden’s syndrome presenting with gastric carcinomas and gastrointestinal polyposis</article-title>
<source/>Nat. Clin. Pract. Gastroenterol. Hepatol.
          <year>2009</year>
<volume>6</volume>
<fpage>184</fpage>
<lpage>189</lpage>
<pub-id pub-id-type="doi">10.1038/ncpgasthep1359</pub-id>
<pub-id pub-id-type="pmid">19190598</pub-id>
</element-citation>
</ref>
<ref id="B39-cancers-11-00844">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marques</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ramalho</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Baldaque-Silva</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Macedo</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Novel mutation identified in Cowden syndrome presenting as a gastric adenocarcinoma</article-title>
<source/>Clin. Res. Hepatol. Gastroenterol.
          <year>2013</year>
<volume>37</volume>
<fpage>e131</fpage>
<lpage>e132</lpage>
<pub-id pub-id-type="doi">10.1016/j.clinre.2013.02.013</pub-id>
<pub-id pub-id-type="pmid">24099866</pub-id>
</element-citation>
</ref>
<ref id="B40-cancers-11-00844">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Makis</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ciarallo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hickeson</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The use of (1)(8)f-fdg pet/ct in Cowden syndrome to differentiate multifocal gastric carcinoma from extensive benign gastric polyposis</article-title>
<source/>Clin. Nucl. Med.
          <year>2012</year>
<volume>37</volume>
<fpage>311</fpage>
<lpage>314</lpage>
<pub-id pub-id-type="doi">10.1097/RLU.0b013e31823ea44d</pub-id>
<pub-id pub-id-type="pmid">22310267</pub-id>
</element-citation>
</ref>
<ref id="B41-cancers-11-00844">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tzortzatos</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Aravidis</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lindblom</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mints</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tham</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Screening for germline phosphatase and tensin homolog-mutations in suspected Cowden syndrome and Cowden syndrome-like families among uterine cancer patients</article-title>
<source/>Oncol. Lett.
          <year>2015</year>
<volume>9</volume>
<fpage>1782</fpage>
<lpage>1786</lpage>
<pub-id pub-id-type="doi">10.3892/ol.2015.2890</pub-id>
<pub-id pub-id-type="pmid">25789042</pub-id>
</element-citation>
</ref>
<ref id="B42-cancers-11-00844">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahdi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mester</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Nizialek</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Ngeow</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Michener</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Germline <italic>PTEN</italic>, sdhb-d, and klln alterations in endometrial cancer patients with Cowden and Cowden-like syndromes: An international, multicenter, prospective study</article-title>
<source/>Cancer
          <year>2015</year>
<volume>121</volume>
<fpage>688</fpage>
<lpage>696</lpage>
<pub-id pub-id-type="doi">10.1002/cncr.29106</pub-id>
<pub-id pub-id-type="pmid">25376524</pub-id>
</element-citation>
</ref>
<ref id="B43-cancers-11-00844">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ring</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Bruegl</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Elkin</surname>
<given-names>E.P.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hartman</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Daniels</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Broaddus</surname>
<given-names>R.R.</given-names>
</name>
</person-group>
<article-title>Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort</article-title>
<source/>Mod. Pathol.
          <year>2016</year>
<volume>29</volume>
<fpage>1381</fpage>
<lpage>1389</lpage>
<pub-id pub-id-type="doi">10.1038/modpathol.2016.135</pub-id>
<pub-id pub-id-type="pmid">27443514</pub-id>
</element-citation>
</ref>
<ref id="B44-cancers-11-00844">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Black</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bogomolniy</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Robson</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Offit</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Barakat</surname>
<given-names>R.R.</given-names>
</name>
<name>
<surname>Boyd</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Evaluation of germline <italic>PTEN</italic> mutations in endometrial cancer patients</article-title>
<source/>Gynecol. Oncol.
          <year>2005</year>
<volume>96</volume>
<fpage>21</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="doi">10.1016/j.ygyno.2004.09.024</pub-id>
<pub-id pub-id-type="pmid">15589575</pub-id>
</element-citation>
</ref>
<ref id="B45-cancers-11-00844">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greene</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>J.R.</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Doyle</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Cowden’s disease with associated malignant melanoma</article-title>
<source/>Int. J. Dermatol.
          <year>1984</year>
<volume>23</volume>
<fpage>466</fpage>
<lpage>467</lpage>
<pub-id pub-id-type="doi">10.1111/ijd.1984.23.7.466</pub-id>
<pub-id pub-id-type="pmid">6490291</pub-id>
</element-citation>
</ref>
<ref id="B46-cancers-11-00844">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Longy</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lacombe</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Cowden disease. Report of a family and review</article-title>
<source/>Ann. Genet.
          <year>1996</year>
<volume>39</volume>
<fpage>35</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="pmid">9297442</pub-id>
</element-citation>
</ref>
<ref id="B47-cancers-11-00844">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reifenberger</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rauch</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Beckmann</surname>
<given-names>M.W.</given-names>
</name>
<name>
<surname>Megahed</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ruzicka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Reifenberger</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Cowden’s disease: Clinical and molecular genetic findings in a patient with a novel <italic>PTEN</italic> germline mutation</article-title>
<source/>Br. J. Dermatol.
          <year>2003</year>
<volume>148</volume>
<fpage>1040</fpage>
<lpage>1046</lpage>
<pub-id pub-id-type="doi">10.1046/j.1365-2133.2003.05322.x</pub-id>
<pub-id pub-id-type="pmid">12786840</pub-id>
</element-citation>
</ref>
<ref id="B48-cancers-11-00844">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salem</surname>
<given-names>O.S.</given-names>
</name>
<name>
<surname>Steck</surname>
<given-names>W.D.</given-names>
</name>
</person-group>
<article-title>Cowden’s disease (multiple hamartoma and neoplasia syndrome). A case report and review of the English literature</article-title>
<source/>J. Am. Acad. Dermatol.
          <year>1983</year>
<volume>8</volume>
<fpage>686</fpage>
<lpage>696</lpage>
<pub-id pub-id-type="doi">10.1016/S0190-9622(83)70081-2</pub-id>
<pub-id pub-id-type="pmid">6863628</pub-id>
</element-citation>
</ref>
<ref id="B49-cancers-11-00844">
<label>49.</label>
<element-citation publication-type="web">
<person-group person-group-type="author">
<collab>American Cancer Society</collab>
</person-group>
<article-title>Lifetime risk of developing or dying from cancer</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.cancer.org/cancer/cancer-basics/lifetime-probability-of-developing-or-dying-from-cancer.html">https://www.cancer.org/cancer/cancer-basics/lifetime-probability-of-developing-or-dying-from-cancer.html</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2019-05-01">(accessed on 1 May 2019)</date-in-citation>
</element-citation>
</ref>
<ref id="B50-cancers-11-00844">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pilarski</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Cowden syndrome: A critical review of the clinical literature</article-title>
<source/>J. Genet. Couns.
          <year>2009</year>
<volume>18</volume>
<fpage>13</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="doi">10.1007/s10897-008-9187-7</pub-id>
<pub-id pub-id-type="pmid">18972196</pub-id>
</element-citation>
</ref>
<ref id="B51-cancers-11-00844">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ngeow</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mester</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rybicki</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Milas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline <italic>PTEN</italic>, SDH, or KLLN alterations</article-title>
<source/>J. Clin. Endocrinol. Metab.
          <year>2011</year>
<volume>96</volume>
<fpage>E2063</fpage>
<lpage>E2071</lpage>
<pub-id pub-id-type="doi">10.1210/jc.2011-1616</pub-id>
<pub-id pub-id-type="pmid">21956414</pub-id>
</element-citation>
</ref>
<ref id="B52-cancers-11-00844">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laury</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Bongiovanni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tille</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Kozakewich</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nose</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Thyroid pathology in <italic>PTEN</italic>-hamartoma tumor syndrome: Characteristic findings of a distinct entity</article-title>
<source/>Thyroid
          <year>2011</year>
<volume>21</volume>
<fpage>135</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="doi">10.1089/thy.2010.0226</pub-id>
<pub-id pub-id-type="pmid">21190448</pub-id>
</element-citation>
</ref>
<ref id="B53-cancers-11-00844">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagy</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ganapathi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Comeras</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Orloff</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ringel</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Kloos</surname>
<given-names>R.T.</given-names>
</name>
</person-group>
<article-title>Frequency of germline <italic>PTEN</italic> mutations in differentiated thyroid cancer</article-title>
<source/>Thyroid
          <year>2011</year>
<volume>21</volume>
<fpage>505</fpage>
<lpage>510</lpage>
<pub-id pub-id-type="doi">10.1089/thy.2010.0365</pub-id>
<pub-id pub-id-type="pmid">21417916</pub-id>
</element-citation>
</ref>
<ref id="B54-cancers-11-00844">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pal</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hamel</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Vesprini</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sanders</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Quercia</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ng Cheong</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Foulkes</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Narod</surname>
<given-names>S.A.</given-names>
</name>
</person-group>
<article-title>Double primary cancers of the breast and thyroid in women: Molecular analysis and genetic implications</article-title>
<source/>Fam. Cancer
          <year>2001</year>
<volume>1</volume>
<fpage>17</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="doi">10.1023/A:1011541424424</pub-id>
<pub-id pub-id-type="pmid">14574011</pub-id>
</element-citation>
</ref>
<ref id="B55-cancers-11-00844">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haibach</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Burns</surname>
<given-names>T.W.</given-names>
</name>
<name>
<surname>Carlson</surname>
<given-names>H.E.</given-names>
</name>
<name>
<surname>Burman</surname>
<given-names>K.D.</given-names>
</name>
<name>
<surname>Deftos</surname>
<given-names>L.J.</given-names>
</name>
</person-group>
<article-title>Multiple hamartoma syndrome (Cowden’s disease) associated with renal cell carcinoma and primary neuroendocrine carcinoma of the skin (merkel cell carcinoma)</article-title>
<source/>Am. J. Clin. Pathol.
          <year>1992</year>
<volume>97</volume>
<fpage>705</fpage>
<lpage>712</lpage>
<pub-id pub-id-type="doi">10.1093/ajcp/97.5.705</pub-id>
<pub-id pub-id-type="pmid">1575215</pub-id>
</element-citation>
</ref>
<ref id="B56-cancers-11-00844">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lynch</surname>
<given-names>E.D.</given-names>
</name>
<name>
<surname>Ostermeyer</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Arena</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dann</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Swisshelm</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Suchard</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>MacLeod</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Kvinnsland</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inherited mutations in <italic>PTEN</italic> that are associated with breast cancer, Cowden syndrome and juvenile polyposis</article-title>
<source/>Am. J. Hum. Genet.
          <year>1997</year>
<volume>61</volume>
<fpage>1254</fpage>
<lpage>1260</lpage>
<pub-id pub-id-type="doi">10.1086/301639</pub-id>
<pub-id pub-id-type="pmid">9399897</pub-id>
</element-citation>
</ref>
<ref id="B57-cancers-11-00844">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shuch</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ricketts</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Vocke</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Komiya</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Middelton</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Kauffman</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>Merino</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Metwalli</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Dennis</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Linehan</surname>
<given-names>W.M.</given-names>
</name>
</person-group>
<article-title>Germline <italic>PTEN</italic> mutation Cowden syndrome: An underappreciated form of hereditary kidney cancer</article-title>
<source/>J. Urol.
          <year>2013</year>
<volume>190</volume>
<fpage>1990</fpage>
<lpage>1998</lpage>
<pub-id pub-id-type="doi">10.1016/j.juro.2013.06.012</pub-id>
<pub-id pub-id-type="pmid">23764071</pub-id>
</element-citation>
</ref>
<ref id="B58-cancers-11-00844">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mester</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Prescott</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Papillary renal cell carcinoma is associated with <italic>PTEN</italic> hamartoma tumor syndrome</article-title>
<source/>Urology
          <year>2012</year>
<volume>79</volume>
<fpage>1187 e1</fpage>
<lpage>1187 e7</lpage>
<pub-id pub-id-type="doi">10.1016/j.urology.2011.12.025</pub-id>
<pub-id pub-id-type="pmid">22381246</pub-id>
</element-citation>
</ref>
<ref id="B59-cancers-11-00844">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parisi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dinulos</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Leppid</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Sybert</surname>
<given-names>V.P.</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hudgins</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>The spectrum and evolution of phenotypic findings in <italic>PTEN</italic> mutation positive cases of Bannayan-Riley-Ruvalcaba syndrome</article-title>
<source/>J. Med. Genet.
          <year>2001</year>
<volume>38</volume>
<fpage>52</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.38.1.52</pub-id>
<pub-id pub-id-type="pmid">11332402</pub-id>
</element-citation>
</ref>
<ref id="B60-cancers-11-00844">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lachlan</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Lucassen</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Bunyan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Temple</surname>
<given-names>I.K.</given-names>
</name>
</person-group>
<article-title>Cowden syndrome and bannayan riley ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: Results of a clinical study of <italic>PTEN</italic> mutation carriers</article-title>
<source/>J. Med. Genet.
          <year>2007</year>
<volume>44</volume>
<fpage>579</fpage>
<lpage>585</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2007.049981</pub-id>
<pub-id pub-id-type="pmid">17526800</pub-id>
</element-citation>
</ref>
<ref id="B61-cancers-11-00844">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mester</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Tilot</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Rybicki</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Frazier</surname>
<given-names>T.W.</given-names>
<suffix>2nd</suffix>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Analysis of prevalence and degree of macrocephaly in patients with germline <italic>PTEN</italic> mutations and of brain weight in <italic>PTEN</italic> knock-in murine model</article-title>
<source/>Eur. J. Hum. Genet.
          <year>2011</year>
<volume>19</volume>
<fpage>763</fpage>
<lpage>768</lpage>
<pub-id pub-id-type="doi">10.1038/ejhg.2011.20</pub-id>
<pub-id pub-id-type="pmid">21343951</pub-id>
</element-citation>
</ref>
<ref id="B62-cancers-11-00844">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hansen-Kiss</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Beinkampen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Adler</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Frazier</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Prior</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Erdman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Herman</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>A retrospective chart review of the features of <italic>PTEN</italic> hamartoma tumour syndrome in children</article-title>
<source/>J. Med. Genet.
          <year>2017</year>
<volume>54</volume>
<fpage>471</fpage>
<lpage>478</lpage>
<pub-id pub-id-type="doi">10.1136/jmedgenet-2016-104484</pub-id>
<pub-id pub-id-type="pmid">28526761</pub-id>
</element-citation>
</ref>
<ref id="B63-cancers-11-00844">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vanderver</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tonduti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Medne</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Vento</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chapman</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Lanpher</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pearl</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gropman</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characteristic brain magnetic resonance imaging pattern in patients with macrocephaly and <italic>PTEN</italic> mutations</article-title>
<source/>Am. J. Med. Genet. A
          <year>2014</year>
<volume>164</volume>
<fpage>627</fpage>
<lpage>633</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.36309</pub-id>
<pub-id pub-id-type="pmid">24375884</pub-id>
</element-citation>
</ref>
<ref id="B64-cancers-11-00844">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ciaccio</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Saletti</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>D’Arrigo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Esposito</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Alfei</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Moroni</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Tonduti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chiapparini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pantaleoni</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Milani</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Clinical spectrum of <italic>PTEN</italic> mutation in pediatric patients. A bicenter experience</article-title>
<source/>Eur. J. Med. Genet.
          <year>2018</year>
<pub-id pub-id-type="doi">10.1016/j.ejmg.2018.12.001</pub-id>
<pub-id pub-id-type="pmid">30528446</pub-id>
</element-citation>
</ref>
<ref id="B65-cancers-11-00844">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balci</surname>
<given-names>T.B.</given-names>
</name>
<name>
<surname>Davila</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Boafo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sell</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Richer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nikkel</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Armour</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Tomiak</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lines</surname>
<given-names>M.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Broad spectrum of neuropsychiatric phenotypes associated with white matter disease in <italic>PTEN</italic> hamartoma tumor syndrome</article-title>
<source/>Am. J. Med. Genet. B Neuropsychiatr. Genet.
          <year>2018</year>
<volume>177</volume>
<fpage>101</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.32610</pub-id>
<pub-id pub-id-type="pmid">29152901</pub-id>
</element-citation>
</ref>
<ref id="B66-cancers-11-00844">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butler</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Dasouki</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.P.</given-names>
</name>
<name>
<surname>Talebizadeh</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>T.N.</given-names>
</name>
<name>
<surname>Miles</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Stratton</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pilarski</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline <italic>PTEN</italic> tumour suppressor gene mutations</article-title>
<source/>J. Med. Genet.
          <year>2005</year>
<volume>42</volume>
<fpage>318</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2004.024646</pub-id>
<pub-id pub-id-type="pmid">15805158</pub-id>
</element-citation>
</ref>
<ref id="B67-cancers-11-00844">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herman</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Butter</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Enrile</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pastore</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Prior</surname>
<given-names>T.W.</given-names>
</name>
<name>
<surname>Sommer</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Increasing knowledge of <italic>PTEN</italic> germline mutations: Two additional patients with autism and macrocephaly</article-title>
<source/>Am. J. Med. Genet.
          <year>2007</year>
<volume>143</volume>
<fpage>589</fpage>
<lpage>593</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.31619</pub-id>
</element-citation>
</ref>
<ref id="B68-cancers-11-00844">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buxbaum</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Chaste</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nygren</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Goldsmith</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Reichert</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Anckarsater</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Rastam</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Silverman</surname>
<given-names>J.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutation screening of the <italic>PTEN</italic> gene in patients with autism spectrum disorders and macrocephaly</article-title>
<source/>Am. J. Med. Genet. B Neuropsychiatr. Genet.
          <year>2007</year>
<volume>144B</volume>
<fpage>484</fpage>
<lpage>491</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.30493</pub-id>
<pub-id pub-id-type="pmid">17427195</pub-id>
</element-citation>
</ref>
<ref id="B69-cancers-11-00844">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McBride</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Varga</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Pastore</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Prior</surname>
<given-names>T.W.</given-names>
</name>
<name>
<surname>Manickam</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Atkin</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Herman</surname>
<given-names>G.E.</given-names>
</name>
</person-group>
<article-title>Confirmation study of <italic>PTEN</italic> mutations among individuals with autism or developmental delays/mental retardation and macrocephaly</article-title>
<source/>Autism Res.
          <year>2010</year>
<volume>3</volume>
<fpage>137</fpage>
<lpage>141</lpage>
<pub-id pub-id-type="doi">10.1002/aur.132</pub-id>
<pub-id pub-id-type="pmid">20533527</pub-id>
</element-citation>
</ref>
<ref id="B70-cancers-11-00844">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Varga</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Pastore</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Prior</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Herman</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>McBride</surname>
<given-names>K.L.</given-names>
</name>
</person-group>
<article-title>The prevalence of <italic>PTEN</italic> mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly</article-title>
<source/>Genet. Med.
          <year>2009</year>
<volume>11</volume>
<fpage>111</fpage>
<lpage>117</lpage>
<pub-id pub-id-type="doi">10.1097/GIM.0b013e31818fd762</pub-id>
<pub-id pub-id-type="pmid">19265751</pub-id>
</element-citation>
</ref>
<ref id="B71-cancers-11-00844">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Condo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Posar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mari</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Resta</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Renieri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Neri</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Patrizi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Parmeggiani</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Phosphatase and tensin homolog (<italic>PTEN</italic>) gene mutations and autism: Literature review and a case report of a patient with Cowden syndrome, autistic disorder, and epilepsy</article-title>
<source/>J. Child Neurol.
          <year>2012</year>
<volume>27</volume>
<fpage>392</fpage>
<lpage>397</lpage>
<pub-id pub-id-type="doi">10.1177/0883073811420296</pub-id>
<pub-id pub-id-type="pmid">21960672</pub-id>
</element-citation>
</ref>
<ref id="B72-cancers-11-00844">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hobert</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Embacher</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mester</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Frazier</surname>
<given-names>T.W.</given-names>
<suffix>2nd</suffix>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Biochemical screening and <italic>PTEN</italic> mutation analysis in individuals with autism spectrum disorders and macrocephaly</article-title>
<source/>EJHG
          <year>2014</year>
<volume>22</volume>
<fpage>273</fpage>
<lpage>276</lpage>
<pub-id pub-id-type="doi">10.1038/ejhg.2013.114</pub-id>
<pub-id pub-id-type="pmid">23695273</pub-id>
</element-citation>
</ref>
<ref id="B73-cancers-11-00844">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klein</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sharifi-Hannauer</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Martinez-Agosto</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Macrocephaly as a clinical indicator of genetic subtypes in autism</article-title>
<source/>Autism Res.
          <year>2013</year>
<volume>6</volume>
<fpage>51</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.1002/aur.1266</pub-id>
<pub-id pub-id-type="pmid">23361946</pub-id>
</element-citation>
</ref>
<ref id="B74-cancers-11-00844">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodriguez-Escudero</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Oliver</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Andres-Pons</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Molina</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cid</surname>
<given-names>V.J.</given-names>
</name>
<name>
<surname>Pulido</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>A comprehensive functional analysis of <italic>PTEN</italic> mutations: Implications in tumor- and autism-related syndromes</article-title>
<source/>Hum. Mol. Genet.
          <year>2011</year>
<volume>20</volume>
<fpage>4132</fpage>
<lpage>4142</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddr337</pub-id>
<pub-id pub-id-type="pmid">21828076</pub-id>
</element-citation>
</ref>
<ref id="B75-cancers-11-00844">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caliskan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kohlmann</surname>
<given-names>W.K.</given-names>
</name>
<name>
<surname>Affolter</surname>
<given-names>K.E.</given-names>
</name>
<name>
<surname>Downs-Kelly</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kanth</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bronner</surname>
<given-names>M.P.</given-names>
</name>
</person-group>
<article-title>Intramucosal lipomas of the colon implicate Cowden syndrome</article-title>
<source/>Mod. Pathol.
          <year>2018</year>
<volume>31</volume>
<fpage>643</fpage>
<lpage>651</lpage>
<pub-id pub-id-type="doi">10.1038/modpathol.2017.161</pub-id>
<pub-id pub-id-type="pmid">29192650</pub-id>
</element-citation>
</ref>
<ref id="B76-cancers-11-00844">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shaco-Levy</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jasperson</surname>
<given-names>K.W.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Samadder</surname>
<given-names>N.J.</given-names>
</name>
<name>
<surname>Burt</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Ying</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bronner</surname>
<given-names>M.P.</given-names>
</name>
</person-group>
<article-title>Gastrointestinal polyposis in Cowden syndrome</article-title>
<source/>J. Clin. Gastroenterol.
          <year>2017</year>
<volume>51</volume>
<fpage>e60</fpage>
<lpage>e67</lpage>
<pub-id pub-id-type="doi">10.1097/MCG.0000000000000703</pub-id>
<pub-id pub-id-type="pmid">27661969</pub-id>
</element-citation>
</ref>
<ref id="B77-cancers-11-00844">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levi</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Baris</surname>
<given-names>H.N.</given-names>
</name>
<name>
<surname>Kedar</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Niv</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Geller</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gal</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gingold</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Morgenstern</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Baruch</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Leach</surname>
<given-names>B.H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Upper and lower gastrointestinal findings in <italic>PTEN</italic> mutation-positive Cowden syndrome patients participating in an active surveillance program</article-title>
<source/>Clin. Transl. Gastroenterol.
          <year>2011</year>
<volume>2</volume>
<fpage>e5</fpage>
<pub-id pub-id-type="doi">10.1038/ctg.2011.4</pub-id>
<pub-id pub-id-type="pmid">23238744</pub-id>
</element-citation>
</ref>
<ref id="B78-cancers-11-00844">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ngeow</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Heald</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Rybicki</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Orloff</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yerian</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Willis</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lehtonen</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Lehtonen</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prevalence of germline <italic>PTEN, BMPR1A, SMAD4, STK11,</italic> and <italic>ENG</italic> mutations in patients with moderate-load colorectal polyps</article-title>
<source/>Gastroenterology
          <year>2013</year>
<volume>144</volume>
<fpage>1402</fpage>
<lpage>1409</lpage>
<pub-id pub-id-type="doi">10.1053/j.gastro.2013.02.001</pub-id>
<pub-id pub-id-type="pmid">23399955</pub-id>
</element-citation>
</ref>
<ref id="B79-cancers-11-00844">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stanich</surname>
<given-names>P.P.</given-names>
</name>
<name>
<surname>Pilarski</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rock</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Frankel</surname>
<given-names>W.L.</given-names>
</name>
<name>
<surname>El-Dika</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>M.M.</given-names>
</name>
</person-group>
<article-title>Colonic manifestations of <italic>PTEN</italic> hamartoma tumor syndrome: Case series and systematic review</article-title>
<source/>World J. Gastroenterol.
          <year>2014</year>
<volume>20</volume>
<fpage>1833</fpage>
<lpage>1838</lpage>
<pub-id pub-id-type="doi">10.3748/wjg.v20.i7.1833</pub-id>
<pub-id pub-id-type="pmid">24587660</pub-id>
</element-citation>
</ref>
<ref id="B80-cancers-11-00844">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shaco-Levy</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jasperson</surname>
<given-names>K.W.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Samadder</surname>
<given-names>N.J.</given-names>
</name>
<name>
<surname>Burt</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Ying</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bronner</surname>
<given-names>M.P.</given-names>
</name>
</person-group>
<article-title>Morphologic characterization of hamartomatous gastrointestinal polyps in Cowden syndrome, peutz-jeghers syndrome, and juvenile polyposis syndrome</article-title>
<source/>Hum. Pathol.
          <year>2016</year>
<volume>49</volume>
<fpage>39</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1016/j.humpath.2015.10.002</pub-id>
<pub-id pub-id-type="pmid">26826408</pub-id>
</element-citation>
</ref>
<ref id="B81-cancers-11-00844">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henderson</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Ngeow</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Putnam</surname>
<given-names>P.E.</given-names>
</name>
<name>
<surname>Abonia</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Marsolo</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rothenberg</surname>
<given-names>M.E.</given-names>
</name>
</person-group>
<article-title>Increased prevalence of eosinophilic gastrointestinal disorders in pediatric <italic>PTEN</italic> hamartoma tumor syndromes</article-title>
<source/>J. Pediatr. Gastroenterol. Nutr.
          <year>2014</year>
<volume>58</volume>
<fpage>553</fpage>
<lpage>560</lpage>
<pub-id pub-id-type="doi">10.1097/MPG.0000000000000253</pub-id>
<pub-id pub-id-type="pmid">24345843</pub-id>
</element-citation>
</ref>
<ref id="B82-cancers-11-00844">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGarrity</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Wagner Baker</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Ruggiero</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Thiboutot</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Hampel</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.P.</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Gi polyposis and glycogenic acanthosis of the esophagus associated with <italic>PTEN</italic> mutation positive Cowden syndrome in the absence of cutaneous manifestations</article-title>
<source/>Am. J. Gastroenterol.
          <year>2003</year>
<volume>98</volume>
<fpage>1429</fpage>
<lpage>1434</lpage>
<pub-id pub-id-type="doi">10.1111/j.1572-0241.2003.07496.x</pub-id>
<pub-id pub-id-type="pmid">12818292</pub-id>
</element-citation>
</ref>
<ref id="B83-cancers-11-00844">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kay</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Soetikno</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Mindelzun</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>H.S.</given-names>
</name>
</person-group>
<article-title>Diffuse esophageal glycogenic acanthosis: An endoscopic marker of Cowden’s disease</article-title>
<source/>Am. J. Proctol. Gastroenterol.
          <year>1997</year>
<volume>92</volume>
<fpage>1038</fpage>
<lpage>1040</lpage>
</element-citation>
</ref>
<ref id="B84-cancers-11-00844">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carlson</surname>
<given-names>H.E.</given-names>
</name>
<name>
<surname>Burns</surname>
<given-names>T.W.</given-names>
</name>
<name>
<surname>Davenport</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Luger</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Spence</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Sparkes</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Orth</surname>
<given-names>D.N.</given-names>
</name>
</person-group>
<article-title>Cowden disease: Gene marker studies and measurements of epidermal growth factor</article-title>
<source/>Am. J. Hum. Genet.
          <year>1986</year>
<volume>38</volume>
<fpage>908</fpage>
<lpage>917</lpage>
<pub-id pub-id-type="pmid">3487976</pub-id>
</element-citation>
</ref>
<ref id="B85-cancers-11-00844">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brownstein</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Mehregan</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Bilowski</surname>
<given-names>J.B.</given-names>
</name>
</person-group>
<article-title>Trichilemmomas in Cowden’s disease</article-title>
<source/>JAMA
          <year>1977</year>
<volume>238</volume>
<fpage>26</fpage>
</element-citation>
</ref>
<ref id="B86-cancers-11-00844">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starink</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Hausman</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>The cutaneous pathology of facial lesions in Cowden’s disease</article-title>
<source/>J. Cutan. Pathol.
          <year>1984</year>
<volume>11</volume>
<fpage>331</fpage>
<lpage>337</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-0560.1984.tb00388.x</pub-id>
<pub-id pub-id-type="pmid">6512062</pub-id>
</element-citation>
</ref>
<ref id="B87-cancers-11-00844">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starink</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Meijer</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Brownstein</surname>
<given-names>M.H.</given-names>
</name>
</person-group>
<article-title>The cutaneous pathology of Cowden’s disease: New findings</article-title>
<source/>J. Cutan. Pathol.
          <year>1985</year>
<volume>12</volume>
<fpage>83</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-0560.1985.tb01607.x</pub-id>
<pub-id pub-id-type="pmid">2582011</pub-id>
</element-citation>
</ref>
<ref id="B88-cancers-11-00844">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masmoudi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chermi</surname>
<given-names>Z.M.</given-names>
</name>
<name>
<surname>Marrekchi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Raida</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Boudaya</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mseddi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jalel</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Turki</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Cowden syndrome</article-title>
<source/>J. Dermatol. Case. Rep.
          <year>2011</year>
<volume>5</volume>
<fpage>8</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="doi">10.3315/jdcr.2011.1063</pub-id>
<pub-id pub-id-type="pmid">21886759</pub-id>
</element-citation>
</ref>
<ref id="B89-cancers-11-00844">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Porter</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cawson</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Scully</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Eveson</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Multiple hamartoma syndrome presenting with oral lesions</article-title>
<source/>Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.
          <year>1996</year>
<volume>82</volume>
<fpage>295</fpage>
<lpage>301</lpage>
<pub-id pub-id-type="doi">10.1016/S1079-2104(96)80355-6</pub-id>
<pub-id pub-id-type="pmid">8884828</pub-id>
</element-citation>
</ref>
<ref id="B90-cancers-11-00844">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brownstein</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Mehregan</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Bikowski</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Lupulescu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Patterson</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>The dermatopathology of Cowden’s syndrome</article-title>
<source/>Br. J. Dermatol.
          <year>1979</year>
<volume>100</volume>
<fpage>667</fpage>
<lpage>673</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2133.1979.tb08070.x</pub-id>
<pub-id pub-id-type="pmid">465314</pub-id>
</element-citation>
</ref>
<ref id="B91-cancers-11-00844">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fargnoli</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Orlow</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Semel-Concepcion</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bolognia</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Clinicopathologic findings in the Bannayan-Riley-Ruvalcaba syndrome</article-title>
<source/>Arch. Dermatol.
          <year>1996</year>
<volume>132</volume>
<fpage>1214</fpage>
<lpage>1218</lpage>
<pub-id pub-id-type="doi">10.1001/archderm.1996.03890340078012</pub-id>
<pub-id pub-id-type="pmid">8859033</pub-id>
</element-citation>
</ref>
<ref id="B92-cancers-11-00844">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oh</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C.W.</given-names>
</name>
</person-group>
<article-title>Case of Cowden syndrome associated with eccrine angiomatous hamartoma</article-title>
<source/>J. Dermatol.
          <year>2007</year>
<volume>34</volume>
<fpage>135</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="doi">10.1111/j.1346-8138.2006.00233.x</pub-id>
<pub-id pub-id-type="pmid">17239153</pub-id>
</element-citation>
</ref>
<ref id="B93-cancers-11-00844">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perez-Nunez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lagares</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Benitez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Urioste</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lobato</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Ricoy</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Ramos</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Lhermitte-Duclos disease and Cowden disease: Clinical and genetic study in five patients with Lhermitte-Duclos disease and literature review</article-title>
<source/>Acta Neurochir.
          <year>2004</year>
<volume>146</volume>
<fpage>679</fpage>
<lpage>690</lpage>
<pub-id pub-id-type="doi">10.1007/s00701-004-0264-x</pub-id>
<pub-id pub-id-type="pmid">15197611</pub-id>
</element-citation>
</ref>
<ref id="B94-cancers-11-00844">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turnbull</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Humeniuk</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Suthers</surname>
<given-names>G.K.</given-names>
</name>
</person-group>
<article-title>Arteriovenous malformations in Cowden syndrome</article-title>
<source/>J. Med. Genet.
          <year>2005</year>
<volume>42</volume>
<fpage>e50</fpage>
<pub-id pub-id-type="doi">10.1136/jmg.2004.030569</pub-id>
<pub-id pub-id-type="pmid">16061556</pub-id>
</element-citation>
</ref>
<ref id="B95-cancers-11-00844">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jarrett</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Soilleux</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bowling</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Dermoscopy of Cowden syndrome</article-title>
<source/>Arch. Dermatol.
          <year>2009</year>
<volume>145</volume>
<fpage>508</fpage>
<lpage>509</lpage>
<pub-id pub-id-type="doi">10.1001/archdermatol.2009.22</pub-id>
<pub-id pub-id-type="pmid">19380689</pub-id>
</element-citation>
</ref>
<ref id="B96-cancers-11-00844">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Daraji</surname>
<given-names>W.I.</given-names>
</name>
<name>
<surname>Ramsay</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>R.B.</given-names>
</name>
</person-group>
<article-title>Storiform collagenoma as a clue for Cowden disease or <italic>PTEN</italic> hamartoma tumour syndrome</article-title>
<source/>J. Clin. Pathol.
          <year>2007</year>
<volume>60</volume>
<fpage>840</fpage>
<lpage>842</lpage>
<pub-id pub-id-type="doi">10.1136/jcp.2005.033621</pub-id>
<pub-id pub-id-type="pmid">17513505</pub-id>
</element-citation>
</ref>
<ref id="B97-cancers-11-00844">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rapini</surname>
<given-names>R.P.</given-names>
</name>
<name>
<surname>Golitz</surname>
<given-names>L.E.</given-names>
</name>
</person-group>
<article-title>Sclerotic fibromas of the skin</article-title>
<source/>J. Am. Acad. Dermatol.
          <year>1989</year>
<volume>20</volume>
<fpage>266</fpage>
<lpage>271</lpage>
<pub-id pub-id-type="doi">10.1016/S0190-9622(89)70033-5</pub-id>
<pub-id pub-id-type="pmid">2464630</pub-id>
</element-citation>
</ref>
<ref id="B98-cancers-11-00844">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trufant</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>McKinnon</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Greenblatt</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bosenberg</surname>
<given-names>M.W.</given-names>
</name>
</person-group>
<article-title>Colonic ganglioneuromatous polyposis and metastatic adenocarcinoma in the setting of Cowden syndrome: A case report and literature review</article-title>
<source/>Hum. Pathol.
          <year>2012</year>
<volume>43</volume>
<fpage>601</fpage>
<lpage>604</lpage>
<pub-id pub-id-type="doi">10.1016/j.humpath.2011.06.022</pub-id>
<pub-id pub-id-type="pmid">22018627</pub-id>
</element-citation>
</ref>
<ref id="B99-cancers-11-00844">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buisson</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Leclair</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Jacquemont</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Podevin</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Camby</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>David</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Heloury</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Cutaneous lipoma in children: 5 cases with Bannayan-Riley-Ruvalcaba syndrome</article-title>
<source/>J. Pediatr. Surg.
          <year>2006</year>
<volume>41</volume>
<fpage>1601</fpage>
<lpage>1603</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpedsurg.2006.05.013</pub-id>
<pub-id pub-id-type="pmid">16952599</pub-id>
</element-citation>
</ref>
<ref id="B100-cancers-11-00844">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan</surname>
<given-names>O.T.</given-names>
</name>
<name>
<surname>Haghighi</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Hamartomatous polyps of the colon: Ganglioneuromatous, stromal, and lipomatous</article-title>
<source/>Arch. Pathol. Lab. Med.
          <year>2006</year>
<volume>130</volume>
<fpage>1561</fpage>
<lpage>1566</lpage>
<pub-id pub-id-type="pmid">17090203</pub-id>
</element-citation>
</ref>
<ref id="B101-cancers-11-00844">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferran</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bussaglia</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lazaro</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Matias-Guiu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Pujol</surname>
<given-names>R.M.</given-names>
</name>
</person-group>
<article-title>Acral papular neuromatosis: An early manifestation of Cowden syndrome</article-title>
<source/>Br. J. Dermatol.
          <year>2008</year>
<volume>158</volume>
<fpage>174</fpage>
<lpage>176</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2133.2007.08237.x</pub-id>
<pub-id pub-id-type="pmid">17941946</pub-id>
</element-citation>
</ref>
<ref id="B102-cancers-11-00844">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rustad</surname>
<given-names>C.F.</given-names>
</name>
<name>
<surname>Bjornslett</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Heimdal</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Maehle</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Apold</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Moller</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Germline <italic>PTEN</italic> mutations are rare and highly penetrant</article-title>
<source/>Hered. Cancer Clin. Pract.
          <year>2006</year>
<volume>4</volume>
<fpage>177</fpage>
<lpage>185</lpage>
<pub-id pub-id-type="doi">10.1186/1897-4287-4-4-177</pub-id>
<pub-id pub-id-type="pmid">20223021</pub-id>
</element-citation>
</ref>
<ref id="B103-cancers-11-00844">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Velden</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Vreeburg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Smeets</surname>
<given-names>E.E.</given-names>
</name>
<name>
<surname>Schrander-Stumpel</surname>
<given-names>C.T.</given-names>
</name>
<name>
<surname>van Steensel</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Skin abnormalities in individuals with macrocephaly: Cowden disease from a dermatologist’s point of view</article-title>
<source/>Int. J. Dermatol.
          <year>2008</year>
<volume>47</volume>
<fpage>45</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-4632.2008.03960.x</pub-id>
<pub-id pub-id-type="pmid">18986487</pub-id>
</element-citation>
</ref>
<ref id="B104-cancers-11-00844">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaffer</surname>
<given-names>J.V.</given-names>
</name>
<name>
<surname>Kamino</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Witkiewicz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>McNiff</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Orlow</surname>
<given-names>S.J.</given-names>
</name>
</person-group>
<article-title>Mucocutaneous neuromas: An underrecognized manifestation of <italic>PTEN</italic> hamartoma-tumor syndrome</article-title>
<source/>Arch. Dermatol.
          <year>2006</year>
<volume>142</volume>
<fpage>625</fpage>
<lpage>632</lpage>
<pub-id pub-id-type="doi">10.1001/archderm.142.5.625</pub-id>
<pub-id pub-id-type="pmid">16702501</pub-id>
</element-citation>
</ref>
<ref id="B105-cancers-11-00844">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Capitan Canadas</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Salinas Sanchez</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Martinez Castillo</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Labrot Moleon</surname>
<given-names>I.L.</given-names>
</name>
<name>
<surname>Duran Moreno</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sanchez Lopez</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Valencia Laseca</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Multiple oral fibropapillomatosis as an initial manifestation of Cowden syndrome. Case report</article-title>
<source/>Med. Oral Patol. Oral Cir. Bucal.
          <year>2006</year>
<volume>11</volume>
<fpage>E319</fpage>
<lpage>E324</lpage>
<pub-id pub-id-type="pmid">16816815</pub-id>
</element-citation>
</ref>
<ref id="B106-cancers-11-00844">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vasovcak</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Krepelova</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Puchmajerova</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Spicak</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Voska</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Musilova</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mestak</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Martinek</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>A novel mutation of <italic>PTEN</italic> gene in a patient with Cowden syndrome with excessive papillomatosis of the lips, discrete cutaneous lesions, and gastrointestinal polyposis</article-title>
<source/>Eur. J. Gastroenterol. Hepatol.
          <year>2007</year>
<volume>19</volume>
<fpage>513</fpage>
<lpage>517</lpage>
<pub-id pub-id-type="doi">10.1097/MEG.0b013e3280d6ed4b</pub-id>
<pub-id pub-id-type="pmid">17489063</pub-id>
</element-citation>
</ref>
<ref id="B107-cancers-11-00844">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnhill</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Albert</surname>
<given-names>L.S.</given-names>
</name>
<name>
<surname>Shama</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Goldenhersh</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Rhodes</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Sober</surname>
<given-names>A.J.</given-names>
</name>
</person-group>
<article-title>Genital lentiginosis: A clinical and histopathologic study</article-title>
<source/>J. Am. Acad. Dermatol.
          <year>1990</year>
<volume>22</volume>
<fpage>453</fpage>
<lpage>460</lpage>
<pub-id pub-id-type="doi">10.1016/0190-9622(90)70064-O</pub-id>
<pub-id pub-id-type="pmid">2312832</pub-id>
</element-citation>
</ref>
<ref id="B108-cancers-11-00844">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nuss</surname>
<given-names>D.D.</given-names>
</name>
<name>
<surname>Aeling</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Clemons</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>W.N.</given-names>
</name>
</person-group>
<article-title>Multiple hamartoma syndrome (Cowden’s disease)</article-title>
<source/>Arch. Dermatol.
          <year>1978</year>
<volume>114</volume>
<fpage>743</fpage>
<lpage>746</lpage>
<pub-id pub-id-type="doi">10.1001/archderm.1978.01640170043008</pub-id>
<pub-id pub-id-type="pmid">646396</pub-id>
</element-citation>
</ref>
<ref id="B109-cancers-11-00844">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okunaga</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Takahata</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Iwasaki</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>A case report of Lhermitte-Duclos disease with systematic avms</article-title>
<source/>Brain Nerve
          <year>2003</year>
<volume>55</volume>
<fpage>251</fpage>
<lpage>255</lpage>
<pub-id pub-id-type="pmid">12728507</pub-id>
</element-citation>
</ref>
<ref id="B110-cancers-11-00844">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takaya</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Iwase</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Maehara</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nishiyama</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yamana</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Takei</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kokubo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kohtake</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Furui</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Transcatheter embolization of arteriovenous malformations in Cowden disease</article-title>
<source/>Jpn. Circ. J.
          <year>1999</year>
<volume>63</volume>
<fpage>326</fpage>
<lpage>329</lpage>
<pub-id pub-id-type="doi">10.1253/jcj.63.326</pub-id>
<pub-id pub-id-type="pmid">10475785</pub-id>
</element-citation>
</ref>
<ref id="B111-cancers-11-00844">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weary</surname>
<given-names>P.E.</given-names>
</name>
<name>
<surname>Gorlin</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Gentry</surname>
<given-names>W.C.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Comer</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Greer</surname>
<given-names>K.E.</given-names>
</name>
</person-group>
<article-title>Multiple hamartoma syndrome (Cowden’s disease)</article-title>
<source/>Arch. Dermatol.
          <year>1972</year>
<volume>106</volume>
<fpage>682</fpage>
<lpage>690</lpage>
<pub-id pub-id-type="doi">10.1001/archderm.1972.01620140030010</pub-id>
<pub-id pub-id-type="pmid">4635800</pub-id>
</element-citation>
</ref>
<ref id="B112-cancers-11-00844">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurek</surname>
<given-names>K.C.</given-names>
</name>
<name>
<surname>Howard</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Tennant</surname>
<given-names>L.B.</given-names>
</name>
<name>
<surname>Upton</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Alomari</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Burrows</surname>
<given-names>P.E.</given-names>
</name>
<name>
<surname>Chalache</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Trenor</surname>
<given-names>C.C.</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title><italic>PTEN</italic> hamartoma of soft tissue: A distinctive lesion in <italic>PTEN</italic> syndromes</article-title>
<source/>Am. J. Surg. Pathol.
          <year>2012</year>
<volume>36</volume>
<fpage>671</fpage>
<lpage>687</lpage>
<pub-id pub-id-type="doi">10.1097/PAS.0b013e31824dd86c</pub-id>
<pub-id pub-id-type="pmid">22446940</pub-id>
</element-citation>
</ref>
<ref id="B113-cancers-11-00844">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pimpalwar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yoo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chau</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ashton</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Margolin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Iacobas</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Temporal evolution and management of fast flow vascular anomalies in <italic>PTEN</italic> hamartoma tumor syndrome</article-title>
<source/>Int. J. Angiol.
          <year>2018</year>
<volume>27</volume>
<fpage>158</fpage>
<lpage>164</lpage>
<pub-id pub-id-type="pmid">30154635</pub-id>
</element-citation>
</ref>
<ref id="B114-cancers-11-00844">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanada</surname>
<given-names>K.N.</given-names>
</name>
<name>
<surname>Merin</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Munden</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Friedlander</surname>
<given-names>S.F.</given-names>
</name>
</person-group>
<article-title>A prospective study of cutaneous findings in newborns in the united states: Correlation with race, ethnicity, and gestational status using updated classification and nomenclature</article-title>
<source/>J. Pediatr.
          <year>2012</year>
<volume>161</volume>
<fpage>240</fpage>
<lpage>245</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpeds.2012.02.052</pub-id>
<pub-id pub-id-type="pmid">22497908</pub-id>
</element-citation>
</ref>
<ref id="B115-cancers-11-00844">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindsay</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Boardman</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Farrell</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Testicular hamartomas in Cowden disease</article-title>
<source/>J. Clin. Ultrasound
          <year>2003</year>
<volume>31</volume>
<fpage>481</fpage>
<lpage>483</lpage>
<pub-id pub-id-type="doi">10.1002/jcu.10209</pub-id>
<pub-id pub-id-type="pmid">14595739</pub-id>
</element-citation>
</ref>
<ref id="B116-cancers-11-00844">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woodhouse</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Delahunt</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>English</surname>
<given-names>S.F.</given-names>
</name>
<name>
<surname>Fraser</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Ferguson</surname>
<given-names>M.M.</given-names>
</name>
</person-group>
<article-title>Testicular lipomatosis in Cowden’s syndrome</article-title>
<source/>Mod. Pathol.
          <year>2005</year>
<volume>18</volume>
<fpage>1151</fpage>
<lpage>1156</lpage>
<pub-id pub-id-type="doi">10.1038/modpathol.3800448</pub-id>
<pub-id pub-id-type="pmid">15920539</pub-id>
</element-citation>
</ref>
<ref id="B117-cancers-11-00844">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woodhouse</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ferguson</surname>
<given-names>M.M.</given-names>
</name>
</person-group>
<article-title>Multiple hyperechoic testicular lesions are a common finding on ultrasound in Cowden disease and represent lipomatosis of the testis</article-title>
<source/>Br. J. Radiol.
          <year>2006</year>
<volume>79</volume>
<fpage>801</fpage>
<lpage>803</lpage>
<pub-id pub-id-type="doi">10.1259/bjr/50628431</pub-id>
<pub-id pub-id-type="pmid">16980675</pub-id>
</element-citation>
</ref>
<ref id="B118-cancers-11-00844">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walker</surname>
<given-names>R.N.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Wilkerson</surname>
<given-names>M.L.</given-names>
</name>
</person-group>
<article-title>Testicular hamartomas in a patient with Bannayan-Riley-Ruvalcaba syndrome</article-title>
<source/>J. Ultrasound Med.
          <year>2008</year>
<volume>27</volume>
<fpage>1245</fpage>
<lpage>1248</lpage>
<pub-id pub-id-type="doi">10.7863/jum.2008.27.8.1245</pub-id>
<pub-id pub-id-type="pmid">18645085</pub-id>
</element-citation>
</ref>
<ref id="B119-cancers-11-00844">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rasalkar</surname>
<given-names>D.D.</given-names>
</name>
<name>
<surname>Paunipagar</surname>
<given-names>B.K.</given-names>
</name>
</person-group>
<article-title>Testicular hamartomas and epididymal tumor in a Cowden disease: A case report</article-title>
<source/>Case. Rep. Med.
          <year>2010</year>
<volume>2010</volume>
<fpage>135029</fpage>
<pub-id pub-id-type="doi">10.1155/2010/135029</pub-id>
<pub-id pub-id-type="pmid">20589082</pub-id>
</element-citation>
</ref>
<ref id="B120-cancers-11-00844">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Memon</surname>
<given-names>W.A.</given-names>
</name>
<name>
<surname>Siddiqui</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Testicular lipomatosis in Cowden disease</article-title>
<source/>J. Ayub. Med. Coll. Abbottabad
          <year>2015</year>
<volume>27</volume>
<fpage>925</fpage>
<lpage>926</lpage>
<pub-id pub-id-type="pmid">27004353</pub-id>
</element-citation>
</ref>
<ref id="B121-cancers-11-00844">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Venkatanarasimha</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hilmy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Case 175: Testicular lipomatosis in Cowden disease</article-title>
<source/>Radiology
          <year>2011</year>
<volume>261</volume>
<fpage>654</fpage>
<lpage>658</lpage>
<pub-id pub-id-type="doi">10.1148/radiol.11091151</pub-id>
<pub-id pub-id-type="pmid">22012908</pub-id>
</element-citation>
</ref>
<ref id="B122-cancers-11-00844">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alnajjar</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Sahai</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Keane</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Testicular pain as a presentation of Cowden syndrome</article-title>
<source/>Ann. R. Coll. Surg. Engl.
          <year>2011</year>
<volume>93</volume>
<fpage>e51</fpage>
<lpage>e52</lpage>
<pub-id pub-id-type="doi">10.1308/147870811X582819</pub-id>
<pub-id pub-id-type="pmid">21943449</pub-id>
</element-citation>
</ref>
<ref id="B123-cancers-11-00844">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harper</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Arya</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Buckingham</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>O’Donoghue</surname>
<given-names>E.P.</given-names>
</name>
</person-group>
<article-title>Intratesticular lipoma</article-title>
<source/>Scandinavian J. Urol. Nephrol.
          <year>2002</year>
<volume>36</volume>
<fpage>223</fpage>
<lpage>224</lpage>
<pub-id pub-id-type="doi">10.1080/003655902320131929</pub-id>
<pub-id pub-id-type="pmid">12201940</pub-id>
</element-citation>
</ref>
<ref id="B124-cancers-11-00844">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Abdollahian</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Sinard</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Thyroid disease associated with Cowden syndrome: A meta-analysis</article-title>
<source/>Head Neck
          <year>2013</year>
<volume>35</volume>
<fpage>1189</fpage>
<lpage>1194</lpage>
<pub-id pub-id-type="doi">10.1002/hed.22971</pub-id>
<pub-id pub-id-type="pmid">22431287</pub-id>
</element-citation>
</ref>
<ref id="B125-cancers-11-00844">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dean</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Gharib</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Epidemiology of thyroid nodules</article-title>
<source/>Best Pract. Res. Clin. Endocrinol. Metab.
          <year>2008</year>
<volume>22</volume>
<fpage>901</fpage>
<lpage>911</lpage>
<pub-id pub-id-type="doi">10.1016/j.beem.2008.09.019</pub-id>
<pub-id pub-id-type="pmid">19041821</pub-id>
</element-citation>
</ref>
<ref id="B126-cancers-11-00844">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>McManus</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sippel</surname>
<given-names>R.S.</given-names>
</name>
</person-group>
<article-title>Are there predictors of malignancy in patients with multinodular goiter?</article-title>
<source/>J. Surg. Res.
          <year>2012</year>
<volume>174</volume>
<fpage>207</fpage>
<lpage>210</lpage>
<pub-id pub-id-type="doi">10.1016/j.jss.2011.11.1035</pub-id>
<pub-id pub-id-type="pmid">22341348</pub-id>
</element-citation>
</ref>
<ref id="B127-cancers-11-00844">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmed</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Al-Shaikh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Akhtar</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Hashimoto thyroiditis: A century later</article-title>
<source/>Adv. Anat. Pathol.
          <year>2012</year>
<volume>19</volume>
<fpage>181</fpage>
<lpage>186</lpage>
<pub-id pub-id-type="doi">10.1097/PAP.0b013e3182534868</pub-id>
<pub-id pub-id-type="pmid">22498583</pub-id>
</element-citation>
</ref>
<ref id="B128-cancers-11-00844">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plamper</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schreiner</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Gohlke</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kionke</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Korsch</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kirkpatrick</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Born</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Aretz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Woelfle</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Thyroid disease in children and adolescents with <italic>PTEN</italic> hamartoma tumor syndrome (phts)</article-title>
<source/>Eur. J. Pediatr.
          <year>2018</year>
<volume>177</volume>
<fpage>429</fpage>
<lpage>435</lpage>
<pub-id pub-id-type="doi">10.1007/s00431-017-3067-9</pub-id>
<pub-id pub-id-type="pmid">29273943</pub-id>
</element-citation>
</ref>
<ref id="B129-cancers-11-00844">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Milas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mester</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Metzger</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Berber</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Siperstein</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Should patients with Cowden syndrome undergo prophylactic thyroidectomy?</article-title>
<source/>Surgery
          <year>2012</year>
<volume>152</volume>
<fpage>1201</fpage>
<lpage>1210</lpage>
<pub-id pub-id-type="doi">10.1016/j.surg.2012.08.055</pub-id>
<pub-id pub-id-type="pmid">23158187</pub-id>
</element-citation>
</ref>
<ref id="B130-cancers-11-00844">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Marqusee</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Webb</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nose</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Fishman</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Shamberger</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Frates</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>S.A.</given-names>
</name>
</person-group>
<article-title>Thyroid nodules and cancer in children with <italic>PTEN</italic> hamartoma tumor syndrome</article-title>
<source/>J. Clin. Endocrinol. Metab.
          <year>2011</year>
<volume>96</volume>
<fpage>34</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="doi">10.1210/jc.2010-1315</pub-id>
<pub-id pub-id-type="pmid">20962022</pub-id>
</element-citation>
</ref>
<ref id="B131-cancers-11-00844">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schrager</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gruener</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Tsou</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Peacocke</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Clinical and pathological features of breast disease in Cowden’s syndrome: An underrecognised syndrome with an increased risk of breast cancer</article-title>
<source/>Hum. Pathol.
          <year>1997</year>
<volume>29</volume>
<fpage>47</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1016/S0046-8177(98)90389-6</pub-id>
</element-citation>
</ref>
<ref id="B132-cancers-11-00844">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sabate</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Torrubia</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Blancas</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sanchez</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Alonso</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Lerma</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Evaluation of breast involvement in relation to Cowden syndrome: A radiological and clinicopathological study of patients with <italic>PTEN</italic> germ-line mutations</article-title>
<source/>Eur. Radiol.
          <year>2006</year>
<volume>16</volume>
<fpage>702</fpage>
<lpage>706</lpage>
<pub-id pub-id-type="doi">10.1007/s00330-005-2877-8</pub-id>
<pub-id pub-id-type="pmid">16208511</pub-id>
</element-citation>
</ref>
<ref id="B133-cancers-11-00844">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eissing</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ripken</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Schreibelt</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Westdorp</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ligtenberg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Netea-Maier</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Netea</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>I.J.M.</given-names>
</name>
<name>
<surname>Hoogerbrugge</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title><italic>PTEN</italic> hamartoma tumor syndrome and immune dysregulation</article-title>
<source/>Transl. Oncol.
          <year>2019</year>
<volume>12</volume>
<fpage>361</fpage>
<lpage>367</lpage>
<pub-id pub-id-type="doi">10.1016/j.tranon.2018.11.003</pub-id>
<pub-id pub-id-type="pmid">30504085</pub-id>
</element-citation>
</ref>
<ref id="B134-cancers-11-00844">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sloot</surname>
<given-names>Y.J.E.</given-names>
</name>
<name>
<surname>Rabold</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Netea</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Smit</surname>
<given-names>J.W.A.</given-names>
</name>
<name>
<surname>Hoogerbrugge</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Netea-Maier</surname>
<given-names>R.T.</given-names>
</name>
</person-group>
<article-title>Effect of <italic>PTEN</italic> inactivating germline mutations on innate immune cell function and thyroid cancer-induced macrophages in patients with <italic>PTEN</italic> hamartoma tumor syndrome</article-title>
<source/>Oncogene
          <year>2019</year>
<pub-id pub-id-type="doi">10.1038/s41388-019-0685-x</pub-id>
<pub-id pub-id-type="pmid">30670777</pub-id>
</element-citation>
</ref>
<ref id="B135-cancers-11-00844">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brandmaier</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>S.Q.</given-names>
</name>
<name>
<surname>Demaria</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Formenti</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>W.H.</given-names>
</name>
</person-group>
<article-title><italic>PTEN</italic> at the interface of immune tolerance and tumor suppression</article-title>
<source/>Front. Biol.
          <year>2017</year>
<volume>12</volume>
<fpage>163</fpage>
<lpage>174</lpage>
<pub-id pub-id-type="doi">10.1007/s11515-017-1443-5</pub-id>
<pub-id pub-id-type="pmid">29527223</pub-id>
</element-citation>
</ref>
<ref id="B136-cancers-11-00844">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Driessen</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>H</surname>
<given-names>I.J.</given-names>
</name>
<name>
<surname>Wentink</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yntema</surname>
<given-names>H.G.</given-names>
</name>
<name>
<surname>van Hagen</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>van Strien</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bucciol</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cogulu</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Trip</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nillesen</surname>
<given-names>W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased PI3K/Akt activity and deregulated humoral immune response in human <italic>PTEN</italic> deficiency</article-title>
<source/>J. Allergy Clin. Immunol.
          <year>2016</year>
<volume>138</volume>
<fpage>1744</fpage>
<lpage>1747</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaci.2016.07.010</pub-id>
<pub-id pub-id-type="pmid">27531073</pub-id>
</element-citation>
</ref>
<ref id="B137-cancers-11-00844">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Handel</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ngeow</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huhn</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.T.</given-names>
</name>
<name>
<surname>Heindl</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Berbers</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Hegazy</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Kionke</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Immune dysregulation in patients with <italic>PTEN</italic> hamartoma tumor syndrome: Analysis of FOXP3 regulatory t cells</article-title>
<source/>J. Allergy Clin. Immunol.
          <year>2017</year>
<volume>139</volume>
<fpage>607</fpage>
<lpage>620</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaci.2016.03.059</pub-id>
<pub-id pub-id-type="pmid">27477328</pub-id>
</element-citation>
</ref>
<ref id="B138-cancers-11-00844">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pal</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Barber</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Van de Bunt</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rudge</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Lachlan</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>N.S.</given-names>
</name>
<name>
<surname>Linden</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Wakelam</surname>
<given-names>M.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title><italic>PTEN</italic> mutations as a cause of constitutive insulin sensitivity and obesity</article-title>
<source/>N. Engl. J. Med.
          <year>2012</year>
<volume>367</volume>
<fpage>1002</fpage>
<lpage>1011</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1113966</pub-id>
<pub-id pub-id-type="pmid">22970944</pub-id>
</element-citation>
</ref>
<ref id="B139-cancers-11-00844">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Molfino</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alessandri</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mosillo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Dell’Utri</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Farcomeni</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Amabile</surname>
<given-names>M.I.</given-names>
</name>
<name>
<surname>Laviano</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title><italic>PTEN</italic> expression and its association with glucose control and calorie supplementation in critically ill patients</article-title>
<source/>Clin. Nutr.
          <year>2018</year>
<volume>37</volume>
<fpage>2186</fpage>
<lpage>2190</lpage>
<pub-id pub-id-type="doi">10.1016/j.clnu.2017.10.021</pub-id>
<pub-id pub-id-type="pmid">29154111</pub-id>
</element-citation>
</ref>
<ref id="B140-cancers-11-00844">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>C.Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Stiles</surname>
<given-names>B.L.</given-names>
</name>
</person-group>
<article-title><italic>PTEN</italic>: Tumor suppressor and metabolic regulator</article-title>
<source/>Front. Endocrinol.
          <year>2018</year>
<volume>9</volume>
<fpage>338</fpage>
<pub-id pub-id-type="doi">10.3389/fendo.2018.00338</pub-id>
</element-citation>
</ref>
<ref id="B141-cancers-11-00844">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title><italic>PTEN,</italic> insulin resistance and cancer</article-title>
<source/>Curr. Pharm. Des.
          <year>2017</year>
<volume>23</volume>
<fpage>3667</fpage>
<lpage>3676</lpage>
<pub-id pub-id-type="doi">10.2174/1381612823666170704124611</pub-id>
<pub-id pub-id-type="pmid">28677502</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<table-wrap id="cancers-11-00844-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">cancers-11-00844-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>Revised <italic>PTEN</italic> hamartoma tumor syndrome (PHTS) diagnostic criteria.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Revised <italic>PTEN</italic> Hamartoma Tumor Syndrome (PHTS) Clinical Diagnostic Criteria [<xref ref-type="bibr" rid="B16-cancers-11-00844">16</xref>,<xref ref-type="bibr" rid="B17-cancers-11-00844">17</xref>]</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Operational Diagnosis in an Individual (either of the following):</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   (1) Three or more major criteria, but one must include macrocephaly, Lhermitte–Duclos disease, or gastrointestinal hamartomas; OR</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   (2) Two major and three minor criteria;</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Operational Diagnosis in a Family where One Individual Meets Revised PHTS Clinical Diagnostic Criteria or Has a <italic>PTEN</italic> Mutation:</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   (1) Any two major criteria with or without minor criteria; OR</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   (2) One major and two minor criteria; OR</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   (3) Three minor criteria</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Major Criteria</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   Breast cancer</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   Endometrial cancer (epithelial)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   Thyroid cancer (follicular) </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   Gastrointestinal hamartomas (including ganglioneuromas, but excluding hyperplastic polyps) (≥3)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   Lhermitte–Duclos disease (LDD), adult</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   Macrocephaly (≥97 percentile)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   Macular pigmentation of the glans penis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   Multiple mucocutaneous lesions (any of the following):</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   Multiple trichilemmomas (≥3), at least one biopsy proven</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   Acral keratoses (≥3 palmoplantar keratotic pits and/or acral hyperkeratotic papules)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   Mucocutaneous neuromas (≥3)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   Oral papillomas (particularly on tongue and gingiva), multiple (≥3) OR biopsy-proven OR dermatologist-diagnosed</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Minor Criteria</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   Autism spectrum disorder</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   Colon cancer</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   Esophageal glycogenic acanthosis (≥3)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   Lipomas (≥3)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   Mental retardation (i.e., Intelligence Quotient (IQ) ≤ 75)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   Renal cell carcinoma</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   Testicular lipomatosis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   Thyroid cancer (papillary or follicular variant of papillary)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">   Thyroid structural lesions (e.g., adenoma, multinodular goiter)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">   Vascular anomalies (including multiple intracranial developmental venous anomalies)</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>